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ABSTRACT
EXOSOMES FROM EMBRYONIC STEM CELLS AS A PROPHYLACTIC
VACCINE AGAINST LUNG CANCER

Shuhan Meng
April 20, 2020

The antigenic similarity between embryos and tumors has raised the idea of
using embryonic materials as a preventative vaccine against neoplastic disease.
Indeed, a previous study reported that a vaccine comprised of allogeneic
murine embryonic stem cells (ESCs) and murine fibroblasts expressing
immune-stimulatory granulocyte macrophage-colony stimulating factor (GMCSF) successfully blocked the outgrowth of an implantable lung cancer (Lewis
lung carcinoma; LLC) and lung tumors caused by a combination of a mutagen
followed by chronic pulmonary inflammation. However, such a vaccine is
obviously impractical for application to humans. The use of fibroblasts to
produce GM-CSF is needlessly complicated, and intact live ESCs carry the
hazard of generating embryomas/teratomas.
v

Here, we report the successful development of an alternative prophylactic
vaccine comprised of exosomes/microvesicles derived from murine ESC line
ES-D3 engineered to produce GM-CSF. The prophylactic potential of this
exosome-based vaccine against implanted lung cancer (subcutaneous
inoculation of LLC) was tested by immunizing mice with ESC-derived exosomes
bearing GM-CSF (ES-exo/GM-CSF). Vaccination significantly slowed or
blocked the outgrowth of LLC without any detectable side effects in liver
function, kidney function and blood cell counts, whereas control exosomes
lacking GM-CSF were ineffective against LLC. In an implanted lung tumor
model, examination of tumor-infiltrating immune cells showed robust tumorreactive immune responses in mice vaccinated with the exosomes bearing GMCSF, including an increase in Th1 cytokine responses, CD8+ T effector
responses and CD8+ T effector/T regulatory cell ratio.
To further evaluate the efficacy of ES-exo/GM-CSF vaccination in
preventing lung tumor development, we investigated an experimental
metastasis model where syngeneic LLC cells were administered directly into
the bloodstream of wild-type C57BL/6 mice through tail vein injection, primarily
resulting in pulmonary metastases. Our studies indicate that vaccination with
ES-exo/GM-CSF inhibited metastatic growth of lung tumors. Importantly,
control exosomes without GM-CSF failed to provide little protection against
metastasized pulmonary malignancies. The efficacy of ES-exo/GM-CSF
vaccination was associated with a decrease in tumor-promoting T regulatory
vi

cells, myeloid derived suppressor cells (MDSCs) and macrophages in tumor
infiltrates as well as an increase in cytokine production from intratumoral CD8 +
T cells.
Since the pluripotency is one of the most specialized properties shared
between ESCs and a subset of lung tumor cells, cancer stem cells (CSCs), we
investigated the role of pluripotency of murine ESCs in prophylactic
effectiveness of ESC-based vaccine. The pluripotency of murine ESCs was
significantly reduced when they were differentiated into neuronal cells. The
pluripotency of ESCs was essential for their anchorage-independent growth
potential. Importantly, differentiation decreased the efficacy of ESCs against the
outgrowth of implanted lung tumors. Furthermore, long-term cancer-preventive
potential of ESC vaccine was also inhibited by differentiation. In summary, these
data indicate the importance of pluripotency of ESCs in their prophylactic
efficacy against lung cancer.
While ESC-based vaccine has shown great potential, the antigens
responsible for its prophylactic efficacy had not been identified yet. Since it is
possible that the antibodies generated by ESC vaccine directly bind tumor cells
and initiate antibody-dependent cellular cytotoxicity (ADCC), we employed a
novel immunoproteomic strategy to gain a deep understanding of antigenicity
of ESC-derived vaccine. We examined the comprehensive profiles of antigens
specific for the antibodies induced by vaccines based on intact ES-D3 cells or
exosomes of ES-D3 cells. Antigens shared by ES-D3 cells and lung tumor cells
vii

were identified, among which lung tumor-associated keratin members 8, 16, 17
are candidate antigens responsible for initiating anti-lung tumor immunity
through ADCC.
Overall, based on the antigenic similarities between embryos and lung
tumors, we developed an effective lung cancer vaccine composed of ESCderived exosomes bearing GM-CSF. This vaccine was very effective in
preventing both primary and metastasized lung tumors by evoking tumorspecific immunity. Therefore, we conclude that a similar vaccine derived from
GM-CSF-expressing human ESCs may be applicable to humans with
increased risk of developing lung cancer, such as long-term smoking history,
lung cancer family history, and carcinogen exposure.

Key words: Exosomes, embryonic stem cells, immune-stimulatory granulocyte
macrophage-colony stimulating factor, prophylactic vaccine, lung cancer
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CHAPTER I

OVERVIEW

1.1. Lung cancer therapy overview
Worldwide, lung cancer is the most common cancer among men in terms of
both incidence and mortality [1]. Among women, lung cancer has the third
highest incidence and is the second after breast cancer in mortality. Current
therapeutic strategies for lung cancer include surgery, chemotherapy,
radiotherapy, and emerging immunotherapy. However, surgery can be only
utilized at the very early stages of lung cancer. Additionally, patients must
surpass pulmonary function benchmarks to qualify for surgery. Chemotherapy
and radiotherapy usually serve as maintenance treatment after surgery or as
first-line therapies for patients who are not eligible for surgery. Unfortunately,
non-small cell lung carcinoma (NSCLC), the most prevalent type of lung cancer,
is especially insensitive to chemotherapy or radiation therapy [2]. Most patients
with NSCLC patients are at advanced stages at the time of diagnosis. As a
result, the 5 years survival rate of patients with NSCLC is low [3].
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Due to the limitation of conventional lung cancer treatments, more and
more researchers are focusing on immunotherapy, which promotes the immune
system to attack tumor cells either alone or combined with other
chemotherapeutics. As a promising therapy to improve patient survival, lung
cancer immunotherapy is generally categorized into 5 classes: nonspecific
immune stimulation, T cell transfer, immune checkpoint inhibitors, antibodybased therapy and cancer vaccines [4]. These therapeutic strategies for lung
cancer are at various phases for clinical applications — some are approved to
treat patients, whereas others are still under preclinical studies.
Nonspecific immune stimulation functions by using immunostimulatory
agents, such as interferon alpha (INF-) and certain interleukins, without
targeting cancer cells specifically [4]. T cell transfer therapy is an
immunotherapeutic strategy that engineers immune cells of patients to
eliminate cancer specifically, including tumor-infiltrating lymphocytes (TIL)
therapy and chimeric antigen receptor (CAR) T cell therapy [4]. Immune
checkpoint inhibitors are designed to block the “off” signal from immune
checkpoints, allowing activated T cells to attack neoplastic cells [5]. Among
immune checkpoint inhibitors, antibodies specific for programmed cell death
protein 1 (PD-1) (nivolumab and pembrolizumab) and programmed cell death
protein ligand 1 (PD-L1) (atezolizumab) have been approved by the US Food
and Drug Administration (FDA) to treat patients with NSCLC. Monoclonal
antibodies against molecules involved in lung tumorigenesis have been used in
2

antibody-based therapy to directly kill lung neoplastic cells or deliver tumorkilling agents to them [5]. The best known example of antibody-based therapy
is cetuximab, a monoclonal antibody against the epidermal growth factor
receptor (EGFR), which is combined with conventional chemotherapeutic drugs
to treat NSCLC patients. Finally, cancer vaccines are a type of immunotherapy
to enable the immune system to recognize and destroy lung cancer cells [6].
Despite some progress, it is important to continue developing novel vaccines
that boost human immunity to prevent the initiation and progression of lung
cancer.
1.2. Cancer vaccines
1.2.1. Cancer vaccine classification
A cancer vaccine can either prevent tumor development or treat existing
malignancy by modulating the immune system [6]. While vaccines designed to
prevent cancer initiation and progression are classified as preventive cancer
vaccines, vaccines that treat cancer patients are known as therapeutic cancer
vaccines.
1.2.1.1. Preventive cancer vaccines
Tremendous success has been achieved in developing prophylactic vaccines
against infectious agents. For certain cancer types, the cause of cancer is viral
infection, which is relatively simple compared with the complex processes
involved in the development of other human cancers and well established [6].
3

While liver cancer has been found to be induced by human hepatitis B virus
(HBV), cervical cancer can be caused by human papilloma virus (HPV) infection.
Exploiting the rich experience gained against infectious diseases, researchers
have developed several preventive cancer vaccines to prevent HBV or HPV
infection, resulting in protection against the development of HBV- and HPVcaused cancer. The first preventive cancer vaccine approved by the FDA is an
anti-HBV vaccine [7]. Later, two preventive vaccines, Gardasil® and Cervarix®,
gained FDA approval for clinical application for their protection against infection
of two HPV subtypes (type 16 and 18) that are responsible for 70 percent of
cervical cancer in the world [8].
However, the pathogenesis of most cancer types is very complicated and
many factors contribute to the initiation and progression of cancer [6]. Unlike
viruses, which are foreign to the human immune system and recognized as
“non-self”, these cancer cells more closely resemble their healthy, normal
counterparts in human body. Thus, tumors bearing “self” antigens are able to
evade immune surveillance, making it difficult to develop preventive vaccines.
Therefore, more sophisticated strategies are required to generate effective
vaccines to prevent cancer that is not associated with infection of a particular
virus. It is critical to develop a vaccine that exhibits broader antitumor efficacy
to prevent the outgrowth of various cancers.
1.2.1.2. Therapeutic cancer vaccines
Therapeutic cancer vaccines eliminate tumor cells by promoting human
4

immune system against cancer [6]. Distinct from preventive cancer vaccines,
therapeutic cancer vaccines are designed to target cancer cells directly.
Therefore, therapeutic cancer vaccines are used to treat patients with
established cancers. Normally, therapeutic cancer vaccines may be generated
by patients’ own cells, including tumor cells and dendritic cells, which promote
robust immune responses against cancer. Sipuleucel-T, a dendritic cell vaccine,
is the first immunotherapy product approved by the US FDA to treat metastatic,
castration-resistant prostate cancer in men [9]. This vaccine recognizes
prostatic acid phosphatase (PAP), an antigen expressed on prostate cancer
cells, to promote T-cell-mediated immune responses against prostate cancer
cells. Sipuleucel-T is generated by in vitro activation of antigen-presenting cells
(APCs) isolated from a patient’s blood by an immunostimulatory cytokine and
subsequent infusion of activated APCs back into the patient [10]. However, this
expensive vaccination strategy only improves overall survival of patients with
advanced prostate cancer by about 4 months.
Therapeutic cancer vaccines may also be generated from tumorassociated antigens identified on specific types of cancer cells [6]. Such a
vaccine is capable of triggering immune responses in any patient bearing the
antigens. Unfortunately, the majority of vaccine-based therapeutic strategies for
cancer have been largely unsuccessful [11]. The probability of generating a
vaccine with a broad spectrum of anti-cancer activities could be greatly
increased when different tumor-associated antigens presented by various
5

tumors, but not by adult tissues, are accessible to the immune system. This
vaccination strategy is advantageous over other tumor antigen-based
treatments, which have shown limited effectiveness in clinical trials, probably
due to their inherent shortcomings [12].
1.2.2. Cancer vaccines in development
1.2.2.1. Embryonic material-based cancer vaccines
In most tissues, stem cells are the only type of cells capable of self-renewal,
whereas other cell types have a much shorter lifespan of days or weeks [13].
Emerging research about cancer immunization focuses on studying cancer
cells and stem cells due to the similarities between them. An earlier study has
demonstrated that cancer tissue can be viewed as a newborn abnormal organ
formed by the accumulation of tumor cells [14]. To eliminate the side effects of
vaccination, cancer vaccines should be developed to avoid influencing somatic
stem cells.
So far, many of the known cancer cell surface markers can also be detected
on adult stem cells [15]. The similarity in cell markers between tumor cells and
normal stem cells has provided evidence for researchers to envision that
cancers arise from remnant embryonic cells in human body [16]. Except for the
same surface markers, cancer cells and embryonic cells also share some
common properties, including histological morphology, reduced contact
inhibition, high proliferation rate, tissue invasion ability, anaerobic metabolism,
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dedifferentiation status, evasion of immune destruction, secretion of angiogenic
factors, and expression of embryonic genes[17].
The history of immunizing animals with fetal tissues to elicit an antitumor
response dates back a century [18]. It was found that most types of neoplastic
cells express certain embryonal antigens, a phenotype described as
'retrogenetic expression' [19]. Subsequent reports indicate that transplantable
and chemically induced tumors could be prevented by vaccination with
embryonic materials that induce cancer-specific immunity. The antigens shared
between tumors and embryos have been identified during the past century [18]
[20]. Initially, the similarities were thought to be restrained within digestive
related tumors [21]. Subsequent studies came up with the concept of “oncofetal
antigens” that are found only at early stages of embryonic and fetal
development, but are also present in cancerous tissues [22]. The oncofetal
antigens are present in most types of tumors, and embryonic materials were
demonstrated to be effective against implantable tumors [23]. This viewpoint
has been validated using human embryonic material [24] as Klavins et al.
reported that the rabbit antisera against human embryos recognized human
tumors, such as lung, colonic and renal cancer. Additional research has also
provided evidence that embryonic cells induce the production of antibodies
recognizing both tumors and embryos [25]. These results help to support the
notion that vaccination with embryonic materials could potentially stimulate the
immunity against different types of tumors, probably by recognizing the markers
7

shared by cancer cells and embryonic cells.
1.2.2.2. Whole-cell cancer vaccines
Early cancer vaccination strategies focused on using irradiated, autologous
tumor cells, which has the advantage of inducing tumor-specific CD4+ and CD8+
T cell responses against multiple tumor-associated antigens (TAAs) [26].
However, this vaccination approach has been hampered by the challenge of
collecting large amounts of patient-specific, contaminant-free malignant cells.
The efforts to utilize immunostimulatory cytokines as vaccine adjuvants has
greatly advanced progress in this area of research. For instance, GVAX is a
vaccine composed of irradiated, syngeneic tumor cells genetically engineered
to produce the immune stimulatory cytokine granulocyte-macrophage colonystimulating factor (GM-CSF) [27]. GVAX has displayed antitumor capability by
promoting specific, robust, and enduring immune responses in preclinical
studies

either

as

a

monotherapy

or

in

combination

with

other

immunotherapeutic agents. However, two Phase III trials of GVAX for patients
with advanced prostate cancer were terminated in 2008 due to a lack of efficacy.
Five years later, a Phase II clinical trial testing the effectiveness of GVAX
combined with a PD-1 inhibitor to treat pancreatic cancer ended without much
success. Although the exact reasons for the lack of success of GVAX in clinical
trials are unclear, it is conceivable that potent immune evasion mechanisms in
cancerous tissues contributed to the clinical failure of GVAX. Thus, the
likelihood of success is highly increased if a whole-cell vaccine is designed to
8

block the escape of tumors from immune surveillance.
It is now evident that stem-like cells (cancer stem cells; CSCs) and more
differentiated trophoblast-like cells coexist within cancerous tissues [15]. CSCs
have been identified in a large number of human malignancies [15]. The
presence of CSCs is a particular challenge in developing cancer vaccines,
because they play an important role in cancer immune evasion [28]. If CSCs
could be targeted in developing cancer vaccines, their antitumor efficacy would
be greatly enhanced.
Based on the mechanisms by which CSCs escape from the immune system
and antigens shared between fetal tissues and CSCs, vaccines containing
embryonic stem cells (ESCs) have been explored for their effectiveness in
boosting antitumor immunity. Among them, a unique prophylactic vaccine
comprised of irradiated, allogeneic murine ESCs and irradiated murine STO
fibroblasts engineered producing GM-CSF has been generated (ESCs/GMCSF vaccine) [29]. This vaccine effectively inhibited the initiation and
progression of both implantable and carcinogen-induced lung adenocarcinoma
in mice without generating detectable toxicity and autoimmune responses.
Importantly, irradiated GM-CSF-expressing fibroblasts alone failed to protect
against the outgrowth of lung tumors, indicating that the vaccine efficacy is not
elicited by non-specific immune responses against allogeneic, whole cell
antigens. The effectiveness of ESCs/GM-CSF vaccine is linked to the
generation of robust tumor-specific primary and memory CD8+ T effector
9

responses, Th1 cytokine response, decreased tumor-suppressive myeloidderived suppressor cells in the spleen and increased ratio of intratumoral CD8 +
T effector/T regulatory cells (Tregs).
A more recent study lends credence to the idea that undifferentiated stem
cells could function as a vaccine against cancer [30]. Kooreman and colleagues
have utilized irradiated, syngeneic induced pluripotent stem cells (iPSCs) and
the immunostimulatory adjuvant CpG to generate a stem cell-based vaccine.
This vaccine is capable of activating the immune system to recognize the
antigens shared between iPSC and cancer cells to confer antitumor immunity.
This vaccination strategy not only blocked the outgrowth of implanted primary
tumors, but also suppressed the recurrence of resected tumors in an adjuvant
setting in mice. Immunization with the iPSC-based vaccine generated effective
anti-cancer immune responses by a systemic boost in CD4+ T helper and CD8+
cytotoxic T cell responses. This study provides robust evidence for the idea that
embryonic material can function as a potent cancer vaccine.
Similarly, immunization with undifferentiated, pluripotent ESCs in the
absence of any immunostimulatory adjuvant only conferred modest antitumor
function against implantable colorectal and pulmonary malignancies in mouse
models of cancer [25, 31]. All of these studies provide robust evidence for the
idea that ESCs with the help of an immunostimulatory adjuvant can function as
a potent cancer vaccine against embryonal antigens expressing at early
embryonic development stages but not in adult tissues. The key to the success
10

of ESC-based cancer vaccines lies in the fact that oncofetal antigens shared by
both embryos and malignant cells are potentially immunogenic due to their
absence in the ‘self’ repertoire of humans.
1.2.2.3. Peptide cancer vaccines
Recently, tremendous progress has been achieved towards understanding the
unique tumor-associated antigens (TAAs) existing in various tumors. T cells are
known to be able to recognize antigen-originated peptide fragments presented
by major histocompatibility complex (MHC) molecules at the surface of APCs
and subsequently elicit specific immune responses. Thus, the peptide epitopes
derived from TAAs have been explored as antitumor therapeutic vaccines [32].
Compared with whole-cell vaccines, peptide-based vaccination strategies hold
several advantages, such as inexpensive production of peptides in large
quantities at clinical grade, easy administration into cancer patients, and limited
toxicity. However, tumor cells are able to acquire various genetic and epigenetic
changes during the “escape” phase of cancer immunoediting process, fostering
an immunosuppressive tumor microenvironment [33]. This enables malignant
cells to alter their antigenic profiles, such as loss of the expression of MHC
molecules or immunogenic TAAs, thereby evading the recognition by the
immune system. Therefore, a major limitation of peptide-base vaccination is the
resistance to immune elimination conferred by the escape of cancer cells from
immune recognition. In this scenario, tumor subpopulations lacking MHC
molecules or TAAs will be positively selected and propagate as their
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counterparts expressing MHC molecules or TAAs will be eliminated by T cells.
A number of peptide-based cancer vaccines have been developed to utilize
recombinant or synthesized epitopes of immunogenic TAAs, and they are
designed to stimulate immune responses against one or more TAAs [32]. In the
clinic, peptide-based cancer vaccines have generally displayed limited toxicity
with only mild side effects reported. Researchers had high hopes for peptidebased cancer vaccination strategies in the beginning. Indeed, immunization
with peptide-based cancer vaccines elicits certain degrees of immune
responses targeted on tumors, such as production of antitumor cytokines,
infiltration of CD4+ and CD8+ lymphocytes into malignant tissues, and detection
of epitope-specific antibodies in the serum. However, the anti-cancer efficacy
of peptide-based cancer vaccines as standalone therapeutics has been largely
disappointing during a variety of clinical trials. This failure could be attributed to
the immunoediting selection of non-immunogenic tumor cells as well as the
strong immunosuppressive microenvironment promoted by cancer cells.
Therefore, the current phase of developing peptide-based vaccines is focused
on overcoming immunoediting by combination with immunotherapeutic
approaches to reverse immunosuppression and enable tumor-specific immune
responses. This strategy could potentially unlock the full capability of cancer
vaccines and likely provide enduring protection against recurrence of
malignancies.
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1.2.3. Cancer vaccine adjuvants
For cancer vaccination, specific vaccine antigens are normally used in
combination with adjuvants to potentiate and modulate antigen-specific
immune responses [34]. Without an adjuvant, a cancer vaccine only provides
modest effects from antigens alone. An adjuvant could enhance the efficacy of
cancer vaccines through various mechanisms, such as promoting cytokine
production, increasing the association between the antigens and APCs,
prolonging antigen presence in the blood, and activating antitumor immune
cells.
1.2.3.1. Cytokines
Cytokines are a broad group of natural peptides (~5–20 kDa) that function as
important immunomodulating agents. Since cytokines are deeply involved in
normal immune responses, they hold great promise as potential adjuvants for
cancer vaccines [35].
1.2.3.1.1. Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Colony-stimulating factors (CSF) are secreted glycoproteins that were
discovered by chance in the observation of proliferating granulocytes and
macrophages in a tissue culture system [36]. CSFs play an important role in
haematopoietic cell activation, survival, differentiation, and proliferation.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a subtype of
CSF produced by macrophages, T cells, mast cells, natural killer (NK) cells,
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endothelial cells, and fibroblasts [37]. GM-CSF stimulates differentiation,
proliferation of stem cells, and increases the production of macrophages and
dendritic cells necessary for activating T cells. Therefore, GM-CSF is an
essential component of the normal immune cascade.
As a growth factor, GM-CSF primarily functions as a multifunctional
haematopoietin to promote production of several blood cell lineages [37]. In the
case of non-haematopoietic function of GM-CSF, there is still a lot to be
discovered. As a key part component in a number of signaling cascades to
activate the immune system, GM-CSF can stimulate different signaling
pathways in various immune cells to enhance immune responses. For instance,
human T cells can be activated by GM-CSF-mediated increase in MHC-II
expression in neutrophils, which is involved in the toll like receptor 4 (TLR4)
signaling [38]. In monocytes, the expression of toll-like receptor 2 (TLR2) and
tumor necrosis factor alpha (TNF-α) is stimulated by GM-CSF to initiate host
innate immune responses [39]. Moreover, GM-CSF promotes differentiation of
dendritic cells in mouse bone marrow [40]. Specifically, GM-CSF activates
signal transducer and activator of transcription 5 (STAT5) expression in
dendritic cells, which in turn upregulates the cytoplasmic cytokine inducible
SH2domain (CISH) protein and promotes subsequent type 1 dendritic cell
development [40]. Because of its effect on dendritic cell activation, GM-CSF
also plays an important role in differentiation of Th1 type cells, as the expression
of MHC-II molecules and immune response in monocytes and dendritic cells
14

were enhanced when treated with GM-CSF [41].
The impact of GM-CSF on the immune system makes it critical in different
types of diseases related to immune response, particularly cancer. For instance,
GM-CSF has been utilized in a dendritic cell-based vaccine against prostate
cancer, in which a fusion protein consisting of GM-CSF and the prostate cancer
antigen PAP activated patient's dendritic cells before they were reinfused into
the patient to stimulate T cell activation and cancer cell elimination [42]. In
another study, GM-CSF and antisense transforming growth factor (TGF)-β2
were co-expressed in isolated tumor cells from a patient to generate a
autologous cancer vaccine [43]. Similarly, a vaccine against melanoma was
designed with a plasmid encoding both GM-CSF and the tumor antigen MAGE1, which can stimulate an antigen-specific immune response through the
production of IFN- and IL-6 [44]. Moreover, GM-CSF along with IL-12 has been
tested in clinical trials as a treatment against lung cancer [45].
In many preclinical studies, GM-CSF has been investigated as an adjuvant
for prophylactic vaccines protecting against infectious diseases and
malignancies. Due to its modulatory role in immune responses suppressing
tumor growth, Nemunaitis et al. evaluated a vaccine with autologous tumor cells
modified to overexpress GM-CSF in patients with early and advanced stage of
NSCLC [46]. Longer survival was observed in the patients vaccinated with GMCSF-expressing tumor cells compared with those immunized with tumor cells
only. Furthermore, a preclinical study has shown that GM-CSF is essential for
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anti-cancer efficacy of a prophylactic lung cancer vaccine [29]. Overall, these
results provide evidence that GM-CSF possesses the potential as an adjuvant
in prophylactic or therapeutic cancer vaccination.
GM-CSF has been extensively explored for its anti-cancer function to
stimulate tumor antigen presentation by recruiting dendritic cells and mediate
protective immunity by activating CD4+ and CD8+ T cells [47]. It is worthy to
note that GM-CSF is also capable of stimulating tumor progression under
certain circumstances. For instance, GM-CSF appears to enhance proliferation
and invasion of lung cancer cells by increasing productions of gelatinases and
urokinase plasminogen activator [47]. In mesothelioma patients, GM-CSF
produced by tumors stimulates tumor progression through promoting
immunosuppression of granulocytes in tumor microenvironments [48].
Therefore, more studies are warranted to elucidate the complexities of GM-CSF
clinical applications.
1.2.3.1.2. IL-23
IL-23 is a heterodimeric cytokine secreted by activated dendritic cells, which is
composed of the IL-12p40 subunit and IL-23p19 subunit [49]. The main function
of IL-23 in the immune system is stimulating IFN-γ production from CD4+ T cells.
Some studies have revealed that IL-23 promotes immunity to target antigens of
endogenous antitumor immunity [50]. In another research, the immunological
and antitumor effects of IL-23 on gp100-specific vaccination therapy of human
melanoma were examined [51]. In this in vivo experiment, systemic IL-23
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administration alone failed to stimulate effective tumor immunity. However, as
an adjuvant of gp100 peptide immunization, IL-23 helped suppressing tumor
growth through vaccination-induced T cell activation [51]. Moreover, tumorspecific T cell levels increased in spleen but not in tumor tissues. It is also
demonstrated that IL-23 is a potent vaccine adjuvant enhancing intratumoral T
cell effector function, rather than increasing intratumoral T cell number for tumor
suppression. However, IL-23 produced drastic side effects, including the rapid,
systemic, vaccination-independent depletion of nonspecific CD8+ and CD4+ T
cells. Another toxicity of IL-23 was weight loss caused by reduced appetite.
While IL-23 is promising in cancer vaccine adjuvant, further research is required
to fulfill its potential by eliminaing the side effects.
1.2.3.2 CpG
First identified in a bacterial genome, CpG is unmethylated deoxycytidyl (“C”)deoxyguanosine (“G”) dinucleotides linked by a phosphodiester (“p”) bond [52].
Since CpG motifs have been widely discovered in microbial genomes but rarely
identified in vertebrate genomes, they are believed to possess pathogenassociated molecular patterns (PAMPs). It has been found that the pattern
recognition receptor toll like receptor 9 (TLR9) in human B cells and
plasmacytoid dendritic cells is able to recognize the CpG PAMPs to elicit the
innate immune response with the production of Th1 and proinflammatory
cytokines. Due to the critical role of plasmacytoid dendritic cells in triggering
immune responses required for tumor elimination, it is appealing to utilize CpG17

based adjuvants for cancer vaccines.
CpG-based cancer vaccine adjuvants are normally designed as synthetic
short

single-stranded

DNA oligodeoxynucleotide

molecules

containing

unmethylated CpG motifs [52]. As adjuvants for cancer vaccines, CpG
oligonucleotides have been shown to enhance activities of professional APCs
and generate tumor-specific immune responses in pre-clinical studies. In recent
research focusing on an iPSC-based cancer vaccine, CpG oligonucleotides
were employed as adjuvants to help suppressing tumor growth in mice [30]. In
a prophylactic setting, immunization of CpG and irradiated iPSC inhibited breast
cancer, mesothelioma, and melanoma in syngeneic mouse models.
Furthermore, this vaccine blocked the recurrence of melanoma at the original
resection sites. To further explore the immunity induced by this vaccine,
Kooreman and colleagues performed adoptive transfer of iPSC/CpG-primed T
cells to immunocompetent mice bearing breast cancer and tumor-experienced
lymphocytes to iPSC-inoculated non-obese diabetic severe combined
immunodeficiency (NOD-SCID) mice. In both cases, tumor growth was reduced,
indicating that CpG promotes tumor-specific immunity against shared epitopes
between iPSCs and cancer cells.
1.2.3.3. Others
Beyond glycoproteins, cytokines, and CpG oligodeoxynucleotides, other
adjuvants have been explored [53, 54]. For instance, mineral salts have also
been adopted in vaccine formulations, including insoluble aluminum salts and
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calcium phosphate, which can induce early and long-lasting immunity
responses. In addition, bacteria-derived adjuvants, saponin and oil adjuvants
have been proved to display different biological and pharmacological activities
in cancer immunity induced from vaccination.
1.3. Exosomes in cancer therapy
1.3.1. Biogenesis of exosomes
Extracellular vesicles (EVs) are a type of membrane capsule released from
parental cells and range in size from 20 nm to 200 nm in diameter [55]. EVs
were firstly found in 1946 as platelet-derived particles by Chargaff and West
[56]. After a series of studies, EVs were discovered to perform numerous
essential functions in intercellular communication [57-59]. In multicellular
organisms, they can be found in nearly all tissues and body fluids [60]. EVs
regulate physiological and pathological functions by transferring their cargo,
such as proteins and nucleic acids, between cells. Among different subtypes of
EVs, exosomes are small membrane vesicles released from various cell types
into

the

extracellular

space

upon

fusion

of

intermediate

endocytic

compartments, multivesicular bodies (MVBs), with the plasma membrane [61].
1.3.2. Composition of exosomes
As a subtype of EVs, exosomes have spherical or cup-shaped construction and
their size is normally in the range of 30–100 nm in diameter. The existence and
biological function of exosomes have been investigated since the mid-20th
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century [55]. It is now known that exosomes inherit biological functions from
their own parental cells, as they contain biological materials acquired from the
cytosol, including proteins, RNA, double-stranded DNA, and metabolites [62].
These exosomal molecules are either located inside exosomes or associated
with their membrane. Exosomes normally contain general as well as cell typespecific proteins with various bioactivities. The protein profiles of exosomes are
similar to those identified in the endocytic pathway, plasma membrane, or
cytosol [61]. A select set of functional coding (mRNAs) or non-coding
(microRNAs) nucleic acids are also enriched in exosomes. It is hypothesized
that the presence of double-stranded DNA in exosomes from certain types of
cells, particularly cancer cells, could serve as a biomarker [62]. On a similar
note, the metabolomic profiles of exosomes circulating in blood and other biofluids also display diagnostic potential in detecting various diseases, including
cancer [61]. The composition of exosomes could be examined by various
biological techniques, such as western blotting, flow cytometry, and
spectrometry.
1.3.3. Functions of exosomes in tumorigenesis
Tumors are composed of a heterogeneous population of malignant cells along
with resident and infiltrating non-transformed cells [63]. Dynamic interactions
between cancer cells and non-malignant cells are critically involved in every
stage of carcinogenesis, as well as responses to cancer therapies. As major
conveyors of intercellular communication, exosomes play an important role in
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the crosstalk between cancer cells and other types of cells in malignant tissues,
particularly immune cells infiltrating into tumors [64].
Emerging evidence indicates that tumor-derived exosomes profoundly
influence the functions of intratumoral immune cells. In some cases, exosomes
derived from tumors enhance immunity against cancer. For instance, exosomes
derived from melanoma tumors could be recognized by T cells through the
endogenous tumor antigens present on exosomes [65]. Furthermore, exosomal
tumor antigens could be transferred to dendritic cells to elicit robust CD8+ T celldependent antitumor immune response in syngeneic and allogeneic mouse
tumor models [66]. On the other hand, tumor-derived exosomes are also
capable of boosting pro-tumor immune signaling [67]. One example is that
exosomes of a variety of tumors promote tumor-associated macrophages
known to stimulate cancer progression and metastasis.
Immunocyte-derived exosomes also play a multifaceted role in regulating
tumor immunity, rather than just inhibiting or promoting malignancies [68].
Exosomes

released

from

antitumorigenic

immune

cells

often

block

carcinogenesis [68]. Like their parental cells, exosomes originating from
dendritic cells possess high levels of transmembrane TNF, Fas ligand (FasL),
and TNF-related apoptosis-inducing ligand (TRAIL) that induce apoptotic
signaling in a variety of tumors [69]. Furthermore, NK cells are also activated
by exosomes of dendritic cells to produce antitumor cytokines [69]. On a similar
note, exosomes derived from NK cells are enriched in FasL and perforin, which
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eliminate human melanoma cells but not unmalignant cells [70]. In contrast,
exosomes derived from pro-tumor immune cells, such as tumor-associated
macrophages, normally promote tumor evasion from immune surveillance [68].
1.3.4. Exosome-based cancer vaccines
Since tumor-associated antigens or factors stimulating tumor-specific immune
responses are encapsulated in the exosomes from either malignant cells or
certain types of immunocytes, numerous investigations have explored
exosomes as an anti-cancer vaccination strategy [68]. The first study about the
role of exosomes in immunotherapy was conducted in the 1990s, in which the
exosomes isolated from B cells were found to stimulate an antigen-specific T
cell response [71]. Subsequent in-depth characterization of exosomes at the
molecular level and standardized exosome isolation and storage protocols
have greatly advanced pre-clinical and clinical studies of exosome-based
cancer vaccines, which display significant advantages over their cell-based
counterparts. Among exosomes derived from different sources, those
originated from dendritic cells and tumor cells have drawn notable interest due
to their particular biological functions to promote tumor-specific immune
response.
Dendritic cell-derived exosomes (Dexosomes) inherit the ability to initiate
an antigen-specific immune response from their parental cells [72]. These
exosomes are enriched in peptide-MHC-I and peptide-MHC-II complexes that
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are 10–100 times more abundant than those in dendritic cells. In addition,
Dexosomes harbor co-stimulatory factors (e.g. CD40, CD80, and CD86) as well
as other molecules involved in immune responses. Pre-clinical research has
demonstrated that Dexosomes elicit robust antitumor immune responses that
activate cytotoxic T cells and NK cells in vitro and in vivo [72], which paved the
way for human clinical trials of Dexosomes as a cell-free cancer vaccine. Two
phase I clinical trials and one phase II clinical trial of Dexosomes have been
carried out in patients with advanced malignancies. In the first phase I clinical
trial with melanoma patients, exosomes from autologous dendritic cells pulsed
with melanoma-associated antigen (MAGE) peptides were utilized to immunize
stage III/IV melanoma patients. The safety of exosome inoculation was
examined and tumor-specific T cell responses was determined [73]. The
second phase I clinical trial tested a vaccine composed of Dexosomes loaded
with the MAGE tumor antigens in patients with advanced NSCLC [74]. This
Dexosome-based vaccine evoked immune responses in some patients and
exhibited limited toxicity, but its antitumor efficacy appeared to be modest.
Following up the phase I clinical trials, a second generation of Dexosome-based
cancer vaccine was developed [75]. The new vaccine was composed of
exosomes derived from TLR4L- or interferon (IFN)--maturated dendritic cells
that elicited more robust T cell stimulation compared with their counterparts
from immature dendritic cells. This phase II trial of patients with advanced
NSCLC improved upon the limited T cell-mediated immune responses
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observed in the phase I studies and enhanced the capacity of Dexosomes to
boost NK cell-mediated antitumor immunity. Overall, these clinical trials have
demonstrated the feasibility and safety of Dexosome-based vaccine, as well as
the ability of Dexosomes to evoke T cell- and NK cell-based immune responses
in patients with advance malignancies.
Tumor-derived exosomes (Texosomes) have been considered as a specific
stimulus for antitumor immunity, since they are enriched in MHC-I molecules,
antigens, and heat shock proteins (HSPs) that could increase immune
responses, particularly cytotoxic T cell activation [76], [77]. More importantly,
Texosomes evoke immune responses against tumors more effectively than
either irradiated live cancer cells or their lysates [78]. Since Texosomes are
capable of transferring a selection of tumor antigens to dendritic cells, they have
been explored as the carriers for tumor antigens in cancer immunotherapy [68].
Although Texosomes could potentially serve as a cell-free cancer vaccine, in
vitro expansion of purified autologous malignant cells from patients is
challenging in clinical settings. It has been shown that large amount of
Texosomes are present in the biological fluids of patients, such as ascitic fluid
[78]. Due to their high abundance, Texosomes isolated from the ascitic fluid of
patients with advanced colorectal carcinoma (CRC) were investigated for their
potential as a cancer vaccine [79]. Like Texosomes from other sources, ascitesderived Texosomes were enriched in MHC-I and MHC-II molecules, HSPs (e.g.
HSC70, HSP70, and HSP90), co-stimulatory molecules, intercellular cell24

adhesion molecule-1 (ICAM-1), and the classical carcinoembryonic antigen
(CEA) of CRC. A phase I clinical trial was conducted with ascites-derived
Texosomes in the absence of presence of immunostimulatory factor GM-CSF
[79]. This vaccination strategy was safe and well-tolerated in CRC patients.
Importantly, ascites-derived Texosomes along with GM-CSF, but not ascitesderived Texosomes alone, induced beneficial CEA-specific antitumor cytotoxic
T lymphocyte (CTL) response, demonstrating its potential as a cancer vaccine
candidate.
However, it is noteworthy that the Texosomes from some tumor cells
promote tumor growth and angiogenesis [80], as they contain a large part of a
protein repertoire to suppress immune responses or exacerbate tumor cell
proliferation by different molecules. Moreover, Tumor-derived exosomes can
induce resistance to the immune response by decreasing antitumor T cells [78,
81]. The utilization of Texosomes as tumor vaccines depends on the types of
malignancies and the immunogenicity of their antigens. Thus, further research
is needed to unlock the immunogenic potential of Texosomes.
1.4. Hypothesis and significance of the project
Numerous studies have focused on prophylactic vaccines against diseases,
since they can decrease or even eradicate a disease around the world. For
infectious disease control, vaccination is effective, because the pathogen can
be recognized by the immune system after the vaccine provides actively
acquired immunity. However, tumors have not been conquered by antitumor
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vaccination, because tumors cells are recognized as “self” by the immune
system. As a result of tumor cell escaping from immune surveillance, tumors
continue developing and metastasizing. To date, a number of vaccination
strategies stimulating tumor-specific immune responses have been explored as
immunotherapy against cancer, among which tumor cell lysates and tumor
antigens have been extensively studied [82]. However, the therapeutic effects
of most antitumor vaccines are not significant in clinical trials. The only FDAapproved cancer treatment vaccine is Sipuleucel-T that treats metastatic
prostate cancer patients with limited improvement of survival [83].
ESCs display the characteristics of self-renewing and they are multipotent
cells. A vaccine comprised of allogeneic murine ESCs and murine fibroblasts
expressing the immunostimulatory factor GM-CSF successfully blocked the
outgrowth of lung tumors in different mouse models [29]. However, an intact
ESC-based cancer vaccine raises ethical concerns and the potential risks of
inducing teratomas and autoimmunity. Exosomes isolated from ESCs inherit
some functions of ESCs as they possess the antigens of ESCs. Because of the
similarity of antigens between ESCs and tumor cells, it is possible that ESCderived exosomes could serve as a cancer vaccine to suppress tumor growth.
Therefore, we hypothesized that the exosomes derived from ESCs would
function as a novel cell-free vaccine to effectively prevent lung tumor
development in mice. The success of this study will have important implications
for lung cancer prevention and could potentially lead to clinical trials of a similar
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human vaccine.

CONCLUSION
Embryonic materials have a long history of being studied as a preventive
strategy against cancer in animal experiments due to their antigenic similarities
to tumor cells. However, the prophylactic function of ESCs against cancer is still
under investigation. Given that exosomes hold great promise as diagnostic
biomarkers and therapeutic vehicles, using ESC-derived exosomes as a cancer
vaccine possesses high potential to prevent lung cancer development. The
experiments proposed in this study will address significant unanswered
questions pertaining to the potential of ESC-derived exosomes as an immuneprophylactic agent for lung cancer.
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CHAPTER II

EXOSOMES DERIVED FROM MURINE EMBRYONIC STEM CELLS OVEREXPRESSING GM-CSF PREVENT TRANSPLANTED LUNG TUMOR
DEVELOPMENT
INTRODUCTION
An

early

hypothesis

of

tumorigenesis

suggests

that

mutations

in

undifferentiated progenitor cells give rise to malignant cells that are capable of
both self-renewal and differentiation. Interestingly, this theory essentially
predicts the discovery of cancer-initiating cells (CICs) that came over 100 years
later. In the mid-1960s, tumor cells and embryonic stem cells were shown to
possess common gene products such as the oncofetal antigens [84]. During
the next decade, a large number of studies confirmed these findings and
revealed that embryonic antigens are re-expressed in malignant cells from a
number of different tissues and that vaccination of animals with fetal material
can prevent the outgrowth of tumors [18]. It now appears that most, if not all,
types of neoplastic cells express certain embryonal antigens, termed as
“retrogenetic expression” [19]. Many of these embryonic gene products (also
called carcinoembryonic antigens) are not expressed in the adults and thus, are
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not included in the repertoire of ‘self’ during the process of thymic selection that
occurs near the end of gestation. Such ‘non-self’ embryonic antigens are
immunogenic and can prime the immune cells to mount an anti-tumor response
[85]. Exploiting such embryonic antigen immunogenicity, we have designed a
unique stem cell-based vaccine that stimulates the immune system to
recognize shared oncofetal antigens and confers protection against tumors.
In our initial attempts to produce a prophylactic vaccine, we successfully
combined irradiated allogeneic murine embryonic stem cells (ESCs) with
murine STO fibroblasts expressing GM-CSF (STO-GM) as an immune
stimulant (ES cell vaccine) [29]. We discovered that ES cell vaccination was
70–100% effective in preventing both implanted and carcinogen induced lung
adenocarcinomas.[29] Vaccinated mice remained tumor-free over a 90-day
observation period. A very recent study by Kooreman et al. [30] supports our
earlier results albeit with a different form of pluripotent stem cells (induced
pluripotent stem cells; iPSCs) and a different adjuvant (CpG) and lends further
credence to the theory that embryonic material can be an effective prophylactic
vaccine against “other” non-mutated neo-antigens, i.e., tumor antigens derived
from proteins that are only expressed during embryonic development and not
in adult tissues.
Although the ES cell vaccine holds promise for inducing anti-lung cancer
immune responses, such an approach has two obvious problems in terms of
application to humans: (i) The use of whole ESCs—although irradiated—raises
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the risk of generating embryomas/teratomas. (ii) Using murine fibroblasts to
generate GM-CSF is needlessly complicated. To overcome these challenges,
we have attempted to develop an alternative cell-free prophylactic vaccine to
avoid the need for the administration of intact ESCs.
Exosomes are cell-derived nanovesicles [86] (30–100nm) that have
recently gained renewed interest as they possess immense potential for cancer
therapy [87]. Within the cells, invagination and budding from the limiting
membrane of late endosomes, results in formation of vesicles that contain
cytosol and the extracellular domain of transferrin receptors at their surface.
These internal vesicles (called exosomes) are then secreted into extracellular
environment following the fusion of multivesicular endosomes with the
plasma membrane [88]. In vitro and in vivo studies suggest that exosomes can
bind to target-cell membranes, or can fuse with target cells to facilitate the
exchange of membrane proteins and cytosol between two cell types [89].
Importantly, exosomes are also capable of transferring nucleic acids, such as
mRNA and microRNA, which represent a new paradigm of genetic exchange
between cells [89, 90]. Recent studies indicate that exosomes can operate as
potential immunotherapeutic agents, with promising results in pre-clinical
studies of cancer immunotherapy [87]. Exosomes have several advantages
over cell-based therapies, including high bio-availability, bio-stability, and lower
costs [91, 92]. Since exosomes can deliver large amounts of cargo directly to
target cells, this property can be exploited to include therapeutics as well as
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immunostimulatory adjuvants in engineered exosomes [93].
In this study, we first generated murine ESCs engineered to produce GMCSF in amounts similar to those produced by STO fibroblasts in our earlier
study. Then we purified ESC-derived exosomes (ES-exo), thereby producing a
self-contained, relatively stable exosome-based vaccine. Here we show that,
prophylactic vaccination of mice with ESC-exosomes expressing GM-CSF (ESexo/GM-CSF) is very effective in preventing implantable lung tumors with no
detectable toxicity. Importantly, anti-tumor efficacy of the ES-exo/GM-CSF
vaccine is associated with robust CD8+ T effector responses and infiltration of
CD8+ T cells into the tumor, leading to increased intratumoral CD8+ T effector/T
regulatory (Tregs) cell ratio in the tumors. Collectively, our findings provide a
strong rationale for further developing this novel cell-free exosome-based
vaccination strategy for the prevention of cancer.
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MATERIALS AND METHODS
1. Cell culturing
Murine embryonic stem cell line ES-D3 was purchased from ATCC (CRL-11632;
Manassas, VA). To remove exosomes, fetal bovine serum (FBS; SCRR-302020; ATCC) was centrifuged at 100,000 × g for 16 hours at 4°C by a 45Ti rotor
in an ultracentrifuge (OptimaTm L-100XP, Beckman Coulter; Brea, CA). After
centrifugation, serum supernatant was used as exosome-free FBS to culture
ES-D3 cells for exosome preparation. ES-D3 cells were grown in KnockOut™
Dulbecco’s Modified Eagle’s Medium (10-829-018; Thermo Fisher; Waltham,
MA) supplemented with 15% exosome-free FBS, 50 U/ml penicillin (sc45000652; Mediatech; Manassas, VA), 50 μg/ml streptomycin (sc45000-652;
Mediatech), 0.1 mM non-essential amino acids (SH3023801; Thermo Fisher),
2

mM

L-glutamine

(L0131-0100;

VWR;

Radnor,

PA),

0.1

mM

β-

mercaptoethanol (21985023; Thermo Fisher) and 100 units/ml leukemia
inhibitory factor (LIF; ESG1106; Thermo Fisher). ES-D3 cells were cultured in
15-cm tissue culture dishes pre-coated with 0.1% gelatin (ES006B; Thermo
Fisher) for 30 minutes without feeder layer cells as described before[94]. Murine
Lewis lung carcinoma (LLC) cell line was obtained from ATCC (CRL-1642).
Murine mammary carcinoma cell line 4T1 was also acquired from ATCC (CRL2539). LLC and 4T1 cells were cultured in medium containing Dulbecco's
modified eagle's medium (DMEM; SH30243.01; Mediatech), 10% FBS (900108; Gemini; Broderick, CA),100 units/ml penicillin (Mediatech) and 100 µg/ml
streptomycin (Mediatech). ES-D3 cells, LLC cells and 4T1 cells were cultured
in a 5% CO2 humidified incubator at 37oC and were cultured no longer than 6–
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8 weeks before a new vial of cryopreserved cells were thawed. All of our
cryopreserved stocks were prepared at passage two after receipt from ATCC
and were authenticated by ATCC cell bank using the Short Tandem Repeat
(STR) profiling.

2. Plasmids
To generate the plasmid expressing murine GM-CSF cDNA in ES-D3 cells, the
transfection plasmid pEF1α-FD3ER-IRES-hrGFP was acquired from Addgene
(37270; Cambridge, MA). In this plasmid, human polypeptide chain elongation
factor 1α (EF1 α) promoter drives the target cDNA expression along with the
marker protein humanized Renilla reniformis GFP (hrGFP) [95, 96]. pEF1αFD3ER-IRES-hrGFP was first digested with EcoRI to produce the vector
backbone. While self-ligation of the vector backbone produced the empty
expression vector pEF1α-IRES-hrGFP, inserting murine GM-CSF cDNA into
the vector backbone generated pEF1α-mGM-CSF-IRES-hrGFP. All of the
plasmids were sequenced to confirm their identities.

3. Exogenous expression of GM-CSF
ES-D3 cells were transfected with pEF1α-mGM-CSF-IRES-hrGFP or its control
counterpart pEF1α-IRES-hrGFP along with the plasmid pBabe-Neo (1767;
Addgene). pBabe-Neo was co-transfected into ES-D3 cells to facilitate
Briefly, 1.4 x 10 6 ES-D3 cells were

selection of stably transfected cells.

cultured in a gelatin-coated 10-cm tissue culture dish with 10 ml medium for 24
hours, and two dishes of ES-D3 cells were prepared for transfection. Two
plasmid mixtures were transfected into ES-D3 cells: #1: pEF1α-IRES-hrGFP
vector and pBabe-Neo; #2: pEF1α-mGM-CSF-IRES-hrGFP and pBabe-Neo.
33

Transfection was carried out using Lipofectamine 2000® transfection
reagent (11668019; Thermo Fisher) following the manufacturer’s protocol.
Twenty-four hours after transfection, transfected cells were split into two 10-cm
dishes and cultured with neomycin (0.5 mg/ml) to eliminate untransfected cells.
The transfected cells were continuously cultured in the medium containing 0.5
mg/ml neomycin for 2 weeks to generate bulk population of stably transfected
ES-D3 cells.
GFP-positive ES-D3 cells were acquired by flow cytometry sorting (MoFlo;
Beckman Coulter). A single GFP-positive ES-D3 cell was plated into one well
of a gelatin-coated 96-well tissue culture plate containing 1 × 103 parental ESD3 cells in neomycin-free medium. Co-culturing transfected ES-D3 cells with
their untransfected parental counterparts ensures that stably transfected single
ES-D3 cells survive and proliferate as a single clone. Forty-eight hours later,
neomycin was added to 96-well plates with the final concentration of 0.5 mg/ml
to eliminate untransfected parental ES-D3 cells. Once GFP-positive ES-D3
single clones in 96-well tissue grew confluence, they were transferred to
gelatin-coated 6-cm tissue culture dishes. Clonal ES-D3 cell lines were
evaluated for their GFP fluorescence intensity by flow cytometry (FACScalibur;
Beckon Dickinson; Franklin Lakes, NJ). ES-D3 clones expressing either GMCSF or the empty vector with high levels of green fluorescence were identified.

4. Evaluation of pluripotency
The pluripotency of ES-D3 cells was evaluated using a StemflowTM Human and
Mouse Pluripotent Stem Cell Analysis Kit (BDB560477; Beckon Dickinson)
following manufacturer’s protocol. The expression of different pluripotency

34

markers, including SSEA-1, Oct-3/4 and SSEA-4, was measured using flow
cytometry (FACScalibur; Beckon Dickinson).

5. Isolation of exosomes
ES-D3 cells (10 x 106/plate) were plated in 15-cm tissue culture plates
precoated with 0.1% gelatin with 15 ml exosome-free medium per plate. After
culturing for 72 hours, medium was collected and stored at 4 oC up to 1 week
without compromising exosome integrity. The collected medium was
centrifuged at 5,000 × g for 60 minutes at 4°C in a JA-10 rotor using an Avanti®
J-26XPI centrifuge (Beckman Coulter). After centrifugation, the supernatant
was collected and transferred into polycarbonate bottles (355622; Beckman
Coulter) for subsequent ultracentrifugation. The ultracentrifugation was carried
out at 100,000 × g for 90 minutes at 4°C using a 45Ti rotor with an
ultracentrifuge

(OptimaTm

L-100XP,

Beckman

Coulter).

After

ultracentrifugation, the supernatant was removed without disturbing the
exosomal pellets. The tight pellets at the bottom of the centrifuge tubes were
gently washed twice with 1 ml of 1 x PBS to remove any traces of medium.
Then pellets were resuspended in 1 x PBS, and exosome preparations were
quantitated by their protein concentrations using BCA (bicinchoninic acid)
assay (23223; Thermo Fisher). Generally, exosomes containing 4 μg protein
can be acquired from 1 ml of ES-D3 culturing medium. The exosomal
preparations were resuspended at a concentration of 5 μg/μl in 1 x PBS and
stored at -80oC.

6. Transmission electron microscopy (TEM)
To fix the exosomes, samples (3–5 μg/μl) were incubated with 2% EM grade
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paraformaldehyde (15710; Electron Microscopy Sciences; Hatfield, PA) at room
temperature for 2 hours. Then fixed exosomes (10 μl) were loaded on Cu grids
with carbon support film (FF200-Cu; Electron Microscopy Sciences). To stain
the exosomal samples, UranyLess staining solution (22409; Electron
Microscopy Sciences) was dropped on the Cu grids with exosomes for 1 minute
at room temperature as suggested by the manufacturer. After being drained
with a filter paper, the grids were dried overnight at room temperature for TEM
image acquisition. A transmission electron microscope (HT7700; Hitachi; Santa
Clara, CA) was used to acquire TEM images.

7. Evaluating exosomes by western blot analysis
Exosomes were resuspended in 1 x SDS-PAGE at a concentration of 1.2 mg/ml.
Exosome lysates (10 μl) were loaded into each well in a 4–20% Bis-Tris gel
(M42015; GenScript; Piscataway, NJ) and transferred onto PVDF membrane
(IPVH00010; EMD Millipore; Burlington, MA). The membrane was incubated
with appropriate primary and secondary antibodies in blotting buffer (1 x PBS
with 0.2% Tween-20) supplemented with 10% (w/v) non-fat dry milk
(NC9022655; Thermo Fisher).
Proteins were detected using an enhanced chemiluminescence detection
system (32106, Thermo Fisher). Antibodies (Abs) for western blot were: antiAlix mAb (clone AC-15, sc-53540); anti-Annexin V mAb (clone H-3, sc-74438);
anti-CD81 mAb (clone B-11, sc-166029); anti-Flotillin-1 (clone C-2; sc-74566);
anti-CD86 mAb (clone D-6, sc- 28347), anti-cytochrome c mAb (clone A-8, sc13156) from Santa Cruz Biotechnology (Dallas, TX), anti-calnexin pAb (ADISPA-860); anti-protein disulfide isomerase (PDI) pAb (ADI-SPA-890) from Enzo
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(Farmingdale, NY), anti-GAPDH pAb (600-401-A33S) from Rockland (Limerick,
PA), anti-Oxphos COX IV-subunit IV mAb (clone 20E8C12; A21348);
peroxidase-conjugated goat anti-rabbit IgG (31460); peroxidase-conjugated
goat anti-mouse IgG (31430) from Thermo Fisher.

8. ELISA measurement of GM-CSF
To determine GM-CSF protein concentration, a murine GM-CSF ELISA kit
(88733422; Thermo Fisher) was used following the manufacturer’s protocol.
After treated in 100 µl of 1 x PBS with 0.05% Tween-20 at room temperature
for 30 minutes, ESD3 cell culturing medium was added to an ELISA plate
coated with capture antibody at 4oC overnight and washed with 1 x PBS + 0.05%
Tween-20 buffer. Following incubation with detection antibody and avidin-HRP,
the absorbance at 450 nM was determined using a microplate reader
(PowerWave XS; BioTek; Winooski, VT). To test the GM-CSF location in
exosome, GM-CSF protein levels in exosomes were determined using the
same ELISA protocol but with slight modifications. Briefly, exosomes (0.6 µg)
were pre-treated in 100 µl of PBS with or without 0.05% Tween-20 at room
temperature for 30 min. Next, samples were added to an ELISA plate coated
with capture antibody and washed with either PBS alone or PBS + 0.05%
Tween-20 buffer. Following incubation with detection antibody and avidin-HRP,
the absorbance at 450 nM was determined using a microplate reader
(PowerWave XS; BioTek).

9. Mice
Wild-type male C57BL/6 mice and female Balb/c mice were purchased from
Jackson Laboratory (Bar Harbor, ME). Mice were housed at the University of
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Louisville Research Resources Facilities (RRF), which has the American
Association for the Accreditation of Laboratory Animal Care (AAALAC)
Accreditation and the Office for Protection from Research Risks (OPRR) IACUC
Assurance. The facility also strictly follows the "Guide for the Care and Use of
Laboratory Animals" (Institute of Laboratory Animal Resources, National
Research Council, National Academy Press, 1996). The experiments involving
mice were approved by University of Louisville IACUC (protocol number:
18301).

10. Vaccination and implanted tumor challenge
Male C57BL/6 mice and female Balb/c mice (6-8 weeks of age, 8 mice/group)
were immunized twice (days 0 and 7) with vehicle only (1 x PBS, 100 µl/mouse),
225 µg exosomes isolated from ES-D3 cells expressing the empty vector (ESexo) or 225 µg exosomes isolated from ES-D3 cells stably expressing GM-CSF
(ES-exo/GM-CSF). Mice were injected with 1 x PBS or exosomes by
subcutaneously (s.c.) in the right flank. On day 14, following vaccination, mice
were challenged with s.c. inoculation of LLC (0.1 ᵡ 106) or 4T1 (0.1 ᵡ 106) in the
left flank. Tumor growth was monitored by measuring tumor width (W) and
length (L) in mm using calipers every other day and tumor volumes (V) in mm3
were calculated by the following formula: V = (W * W * L) / 2.

11. Evaluation of Fertility
Female C57BL/6 mice (8 weeks of age, 4 mice/group) were immunized twice
(days 0 and 7) with vehicle control (1 x PBS, 100 µl/mouse) or 225 µg exosomes
containing GM-CSF (ES-exo/GM-CSF). The mice were subjected to s.c.
inoculation of vehicle control or exosomes in the right flank. Following two
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weekly vaccinations, each of the female mice from control or vaccination group
was bred with one male C57BL/6 mouse (10 weeks of age). The litter size and
gender ratio were evaluated after newly born mice reached 4 weeks of age.

12. Evaluation of toxicological effects
Female C57BL/6 mice (8 weeks of age, 4 mice/group) were subjected to two
weekly vaccinations with vehicle only (1 x PBS, 100 µl/mouse), 225 µg control
exosomes (ES-exo) or 225 µg exosomes containing GM-CSF (ES-exo/GMCSF). One week after completing the second vaccination, whole blood was
drawn from mice by cardiac puncture immediately following CO2 asphyxiation.
To examine liver and kidney function, whole blood was transferred to serum
separator tubes (365967; Beckon Dickinson). One hour post-collection,
samples were centrifuged for 10 minutes at 10,000 × g, and serum was
collected from each sample and analyzed by the Research Resource Center
(RRC) facility at the University of Louisville for non-steroidal anti-inflammatory
drug (NSAID) toxicological analysis. While the liver function was evaluated by
measuring alanine transaminase (ALT) and alkaline phosphatase (ALP) levels,
kidney damage was assessed by levels of creatinine and blood urea nitrogen
(BUN). Simultaneously, whole blood was collected in EDTA-coated tubes
(365974; Beckon Dickinson) and analyzed by the RRC facility for complete
blood count (CBC) analysis.

13. Flow cytometric analysis.
Single cell suspensions from spleen were stained with relevant antibodies for
30 minutes after blocking with anti-CD16/CD32 antibody for 15 minutes at 4 °C.
After washing, cell surface and intracellularly stained cells were analyzed on a
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FACSCalibur (Becton Dickinson) and results were analyzed with FlowJo
software (TreeStar, Inc., Ashland, OR). Antibodies used for evaluating
splenocytes were: anti-CD3 mAb (clone 17A2, 100222); anti-CD4 mAb (clone
GK1.5; 100406); anti-CD8 mAb (clone 53-6.7; 100712); anti-CD11b mAb (clone
M1/70; 101228); anti-Ly6C mAb (clone HK1.4; 128006); anti-Ly6G mAb (clone
1A8; 127608); anti-CD16/CD32 mAb (clone 2.4G2; 101320) from Biolegend
(San Diego; CA), anti-CD44 mAb (clone IM7; 17-0441-82); anti-CD25 mAb
(clone PC61.5; 45-0251-82) from (Thermo Fisher), anti-CD62L mAb (clone
MEL-14; 553152; BD Biosciences; San Jose, CA).

14. Intracellular cytokine staining
Spleens were isolated from mice in different treatment groups 10 days after the
second vaccination. Splenocytes were stimulated with LLC lysate (50 mg/ml)
or 4T1 lysate (50 mg/ml) for 4 days. For TNF- and IFN- production, effector
cells were harvested and restimulated for 6 hours with respective tumor cell
lysate in the presence of Golgiplug (555029; BD Biosciences) at a
concentration of 1 μl/ml of culture medium. After restimulation, cells were
harvested and Fc receptors were blocked using anti-CD16/CD32 antibody.
Then, cells were stained for surface expression of CD8 and intracellular
expression of cytokines using Cytofix/Cytoperm kit (555029; BD biosciences)
according to the manufacturer’s instructions and analyzed by flow cytometry.

15. Analysis of tumor-infiltrating T cells
Vaccinated and control mice bearing LLC tumors were euthanized 18–21 days
after tumor challenge. Solid tumors were dissected, chopped into small pieces
using surgical scissors, and enzymatically dissociated in HBSS containing 400
40

U/ml collagenase type IV (C9891, Sigma-Aldrich), 0.025 mg/ml hyaluronidase
(H6254, Sigma-Aldrich), 0.01 mg/ml DNase I (D5025, Sigma-Aldrich) for 2
hours at 37 °C with occasional shaking. The resultant cells were washed and
passed through a Ficoll gradient (17144002; GE Healthcare; Chicago, IL) to
eliminate dead cells. Anti-CD45 antibody was used to selectively exclude
CD45− tumor cells from analysis. Tumor infiltrating lymphocytes (TILs) were
then analyzed by flow cytometry for the expression of CD4, CD8, and CD25
markers. Tregs (Foxp3+) were analyzed using the anti-mouse Foxp3 staining kit
(00-5523-00; eBioscience). The same number of cells (based on side-scatter
and forward-scatter analyses) was acquired in all samples. For intracellular
IFN- and TNF- analysis, TILs were stimulated with LLC lysates (50 mg/ml)
for 24 hours and restimulated with LLC lysates for 6 hours in the presence of
Brefeldin A. After restimulation, cells were harvested, treated with Fc block, and
stained for surface expression of CD8 and intracellular expression of cytokines
using Cytofix/Cytoperm kit according to the manufacturer’s instructions
(555029; BD Biosciences) and analyzed by flow cytometry.

16. Statistical analysis
StatView version 5.0.1 software (Windows version; SAS Institute, Cary, NC)
or GraphPad Prism 5.0 software (GraphPad Prisim Software, Inc., La Jolla, CA)
were used for all statistical analyses. Comparisons between groups were done
using Student’s t test or one-way analysis of variance (ANOVA) where
appropriate. Survival curves were analyzed using the log-rank test. Statistical
significance was assumed at p<0.05.

41

RESULTS
1. Exogenous expression of GM-CSF in murine embryonic stem cell ESD3.
The antigenic similarity between embryos and tumors has raised the idea of
using embryonic material as a prophylactic vaccine against cancer [19, 97, 98].
An earlier study reported that a vaccine comprised of allogeneic murine ESCs
and murine STO fibroblasts expressing GM-CSF to amplify immune responses
successfully blocked the outgrowth of different lung tumors in mice [29].
However, this vaccine is impractical for humans for at least two reasons. First,
administering

intact,

live

ESCs

carries

the

risk

of

generating

embryomas/teratomas in MHC-matched recipients. Second, the use of live
fibroblasts to produce GM-CSF is unnecessarily complicated. We sought to
overcome these hurdles by developing an alternative prophylactic vaccine
comprised of exosomes derived from murine ESCs expressing GM-CSF
(Figure 2.1). To this end, we first attempted to stably over-express exogenous
murine GM-CSF in murine ESC cell line ES-D3 (Figure 2.2).
Previous studies have shown that the cellular elongation factor-1a (EF1a)
promoter efficiently drives exogenous gene expression in murine ESCs [99,
100]. Murine GM-CSF cDNA was cloned into the transfection vector pEF1aIRES-hrGFP to generate a corresponding GM-CSF expression vector (Figure
2.2A). This vector expresses both GM-CSF and GFP from the EF1a promoter
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with an IRES sequence allowing us to use the expression of GFP as a marker
to track GM-CSF expression. GM-CSF was stably over-expressed in ES-D3
cells by transfection. Flow cytometry analysis revealed that both GM-CSFexpressing and empty vector control ES-D3 cells express GFP at high levels in
comparison to untransfected parental ES-D3 cells (Figure 2.2B). Once ES-D3
cells stably over-expressing GM-CSF were acquired, the amounts of GM-CSF
secreted into the cell culture medium were determined using a murine GM-CSF
ELISA kit. As shown in Figure 2.2C, the levels of GM-CSF generated by ES-D3
cells over-expressing GM-CSF were roughly equivalent to those produced by
GM-CSF-expressing STO fibroblasts employed in an earlier study [29].

A

B

Figure 2.1. Strategies to generate vaccines against lung cancer.
(A) A previously reported vaccine comprised of allogeneic murine ESCs and
murine fibroblasts expressing GM-CSF to promote immune responses. (B)
An improved prophylactic vaccine comprised of exosomes derived from
murine ESCs expressing GM-CSF.
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Figure 2.2. Exogenous GM-CSF was stably over-expressed in ES-D3
cells.
(A) In the schematic diagram of the plasmid for over-expressing murine GMCSF in ES-D3 cells, an EF1a promoter drives GM-CSF expression and GFP
serves as an expression marker. (B) Fluorescence intensity of GFP in GMCSF-expressing ES-D3 cells or their empty vector control cells was
determined by flow cytometry. (C) GM-CSF levels in transfected ES-D3 cells.
ELISA measurements of GM-CSF concentrations in the medium of the
indicated cells. The data are shown as mean ± standard deviations (mean ±
SD) of three experiments, **, p < 0.001; n.s., not significant; ANOVA with
Tukey’s multiple comparison test.
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2. Murine embryonic stem cells expressing GM-CSF maintain their
pluripotency.
As a cytokine with immunostimulatory function, GM-CSF has been reported to
promote differentiation of hematopoietic progenitor cells [101]. To ensure that
expressing GM-CSF in ES-D3 cells had limited effects on their pluripotent
undifferentiated state, the pluripotency of ES-D3 cells was evaluated using flow
cytometry to examine expression of multiple markers of pluripotency and
differentiation. We assessed cellular expression of pluripotency-associated
markers SSEA-1 and Oct-3/4 along with differentiation-associated marker
SSEA-4. As shown in Figure 2.3, high expression levels of pluripotency markers
SSEA-1 and Oct-3/4 were unchanged in GM-CSF-expressing cells compared
with those in parental and vector control cells, and over 95% of each of parental
and transfected ES-D3 cells were positive for the expression of SSEA-1 and
Oct 3/4. Similarly, expression of the differentiation marker SSEA-4 remained at
low levels in all of the cell lines examined with less than 1% of cells positive for
SSEA-4 expression. Overall, these data provide evidence that over-expressing
GM-CSF does not influence the pluripotency of murine ESCs.
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Figure 2.3. Pluripotency of ES-D3 cells is not affected by GM-CSF
expression.
Flow cytometry analysis of the expression of pluripotency and differentiation
markers (SSEA1, SSEA4 and Oct3/4) in parental, vector control and
GMCSF-expressing ES-D3 cells. The data shown are representative of three
independent flow cytometry assays.
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3. Isolation and characterization of exosomes from murine embryonic
stem cells.
An increasing number of studies suggests that exosomes also exhibit
immunoregulatory and anti-tumor functions [102]. Thus, we reasoned that
exosomes from ES-DS cells expressing GM-CSF could also possess biological
activities to regulate immune responses and prevent tumor growth. To this
purpose, exosomes from ES-D3 cells stably expressing GM-CSF or its empty
vector were isolated after several steps of centrifugation. Exosomes generated
by vector control cells and GM-CSF-transfected cells were examined by TEM
electron microscopy (Figure 2.4A). TEM images revealed that the exosomes
were comprised of vesicles of variable sizes, a common feature of exosomal
preparations [103]. Moreover, the diameters of individual vesicles were 30–100
nM, consistent with earlier reports [104]. Purity of exosomal/microvesicle
material was indicated by positive western blot signals for different exosomal
markers, including CD81, Alix and annexin V, flotillin-1 and CD86. Importantly,
the abundance of exosomal markers was greatly enhanced in ES-D3-derived
exosomes compared with corresponding whole cell extracts. In contrast, the
presence of other subcellular compartment markers in exosomes was not
detected, including (i) endoplasmic reticulum markers – protein disulfide
isomerase (PDI) and calnexin, (ii) mitochondrial markers – cytochrome C and
COX IV-subunit IV, and (iii) the cytosolic marker GAPDH, further demonstrating
the purity of ES-D3-derived exosomal material (Figure 2.4B). To further
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characterize isolated exosomes from ES-D3 cells, we used a proteomics
approach to analyze the profile of exosomal proteins. As expected, well-known
exosomal protein markers, such as CD81, annexin V and Alix, were present in
exosomes obtained from ES-D3 cells [Table 2.1].
A

B

Figure 2.4. Characterization of exosomes isolated from ES-D3 cells.
(A) Exosomes were isolated from ES-D3 cells stably expressing GM-CSF or
the empty vector. Exosomes were examined by transmission electron
microscopy. Arrows indicate individual exosomes, scale bar 100 nM. (B) The
levels of markers for exosomes, endoplasmic reticulum (ER), mitochondria,
and cytosol in the indicated exosomes and whole cell extracts (WCE) were
determined by western blot. PDI, protein disulfide isomerase; cyto C,
cytochrome C. Molecular weight markers (kD) are labeled on the left.
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Table 2.1. Exosomes derived from ES-D3 cells express prototype
exosomal markers.
Exosomal markers in exosomes isolated from ES-D3 cells were identified by
a proteomics approach.
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4. The majority of GM-CSF is localized within exosomes.
As shown earlier (Figure 2.2C), the majority of GM-CSF expressed in ES-D3
cells was extracellularly secreted. The concentrations of GM-CSF in isolated
exosomes were investigated by ELISA. A significant amount of GM-CSF was
detected in the exosomes isolated from ES-D3 cells over-expressing GM-CSF,
but not in those prepared from vector control cells (Figure 2.5A). To further
investigate GM-CSF protein localization in the exosomes, we quantitated
exosomal GM-CSF levels under different experimental conditions through an
ELISA-based approach (Figure 2.5B). Briefly, the detergent Tween-20 (0.05%)
was first employed to permeabilize the exosomal membranes, and ELISA
assays were carried out in buffers with or without 0.05% Tween-20. Since
Tween-20 is known to reduce protein-protein interactions, the background GMCSF levels detected in control exosomes were significantly reduced by Tween20 in the washing buffer. In contrast, the amounts of GM-CSF in the exosomes
isolated from ES-D3 cells expressing GM-CSF were significantly increased by
Tween-20. This result indicates that Tween-20 permeabilized exosomal
membrane, making GM-CSF molecules located inside the exosomes available
for detection. These data suggest that almost all GM-CSF is located in the
lumen of the exosomes derived from ES-D3 cells.
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Figure 2.5. GM-CSF is located within the exosomes
(A) The amounts of GM-CSF in exosomes isolated from vector control ESD3 cells or GM-CSF-expressing ES-D3 cells were evaluated by ELISA. The
data are presented as mean ± SD of three independent experiments. *,
p<0.05; ANOVA with Tukey’s multiple comparison test. (B) The localization
of GM-CSF in exosomes was examined. Exosomes pretreated with or
without 0.05% Tween-20 were added to an ELISA plate. ELISA was carried
out using washing buffer containing either 1 x PBS only or 1 x PBS + 0.05%
Tween-20. The data are shown as mean ± SD of three independent ELISA
experiments. *, p<0.05; ANOVA with Tukey’s multiple comparison test.
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5. Vaccination with GM-CSF-expressing ESC-derived exosomes prevents
the outgrowth of implanted lung adenocarcinoma.
To explore the prophylactic potential of exosomes isolated from ESCs for lung
cancer, a standard vaccination timing regimen was carried out (Figure 2.6A).
Specifically, C57BL/6 mice (n = 20) were immunized twice (days 0 and 7) with
vehicle control, the exosomes of ES-D3 cells expressing empty vector (ES-exo)
or the exosomes of GM-CSF-expressing ES-D3 cells (ES-exo/GM-CSF). Mice
were then challenged with subcutaneous (s.c.) inoculation of Lewis lung
carcinoma (LLC) cells at day 14 and monitored for tumor outgrowth. Robust
protection against tumor initiation and growth was observed only in mice
vaccinated with ES-exo/GM-CSF (Figure 2.6B). Vaccination of mice with ESexo/GM-CSF was 60% effective in preventing tumor outgrowth, whereas all
non-vaccinated control animals developed tumors by day 28 post-challenge.
More importantly, LLC tumors that developed in exo/GM-CSF-vaccinated mice
(n = 8) were significantly smaller and exhibited greatly reduced tumor growth
rate compared with non-vaccinated control and ES-exo-vaccinated mice
(Figure 2.6C). Furthermore, vaccination with ES-exo was completely ineffective
in reducing tumor outgrowth, revealing an essential role of immune-stimulatory
GM-CSF for anti-tumor efficacy of the vaccine.
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Figure 2.6. Vaccinating mice with the exosomes from ESCs expressing
GM-CSF prevents implanted lung tumor growth.
(A) Scheme of immunization. Male C57BL/6 mice were immunized twice with
1 x PBS (control), ES-exo or ES-exo/GM-CSF (Days 0 and 7) prior to s.c.
challenge with LLC at Day 14. (B) Tumor growth was monitored daily in all
animals (20 mice/group) until sacrifice due to tumors exceeding 5% of body
weight. The ES-exo/GM-CSF-vaccinated tumor-free mice remained so for
up to 4 months later with no overt signs of distress. Results are
representative of three independent experiments. ***, p < 0.0001; relative to
control group; log-rank test. (C) Tumor growth was measured with calipers
every 2nd or 3rd day and tumor volumes were plotted as indicated. The data
are represented as mean ± SD the average of tumor volumes of (with 20
mice/ in control group, 8 mice in ES-exo group and 8 mice/in ES-exo/GMCSF group and are representative of three independent experiments. **, p <
0.001; ANOVA with Tukey’s multiple comparison test.
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6. Vaccination with ES-exo/GM-CSF has no toxic side effects in mice.
To evaluate whether any toxic effects are associated with the regimen of two
weekly vaccinations, we examined fertility, kidney function, liver function, and
complete blood count (CBC) in vaccinated and unvaccinated mice. For fertility,
there was no difference in litter sizes between female animals vaccinated with
ES-exo/GM-CSF and their control counterparts (Figure 2.7A). Moreover,
vaccination with ES-exo/GM-CSF did not alter the gender ratio of litters (Figure
2.7B).
As shown in Figures 2.8A-B, the levels of alanine transaminase (ALT) and
alkaline phosphatase (ALP) were similar among control, ES-exo and ESexo/GM-CSF-vaccinated mice, indicating that liver function remained
unchanged after vaccination. To assess kidney function, we measured the
levels of creatinine and blood urea nitrogen (BUN) in serum, and slight changes
in BUN and creatinine levels between the vaccinated group and control group
were detected (Figures 2.8C-D). Finally, complete blood count (CBC) analysis
were carried out (Figures 2.9), showing no significant difference in blood cell
counts among the mice in different experimental groups. Overall, these studies
indicate that vaccination with ES-exo/GM-CSF did not induce any toxic effects
in the immunized mice.
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Figure 2.7. Vaccination with ESC-derived exosomes (ES-exo/GM-CSF)
does not reduce fertility of mice.
Following immunization twice with vehicle control (1 x PBS) or ES-exo/GMCSF (days 0 and 7), female C57BL/6 mice were bred with C57BL/6 male
mice at Day 14. (A)The dot graph showing the litter sizes of unvaccinated
control or ES-exo/GM-CSF-vaccinate female mice (4 mice in each group) on
the date of delivery. The average values of litter sizes are also presented.
n.s., not significant, ANOVA with Tukey’s multiple comparison test. (B)The
numbers of two genders in each litter 4 weeks following birth. The mean
values of the numbers of newly born male or female mice is shown (n = 4
per group, n.s., not significant; ANOVA with Tukey’s multiple comparison
test).
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Figure 2.8. ES-exo/GM-CSF vaccination does not display toxic effects
on functions of kidney and liver.
Male C57BL/6 mice were vaccinated twice with vehicle only (control), ESexo or ES-exo/GM-CSF (days 0 and 7). The serum was collected from each
mouse and functions of liver and kidney were evaluated at Day 14. (A-B)
Liver function was determined by examining the levels of alanine
aminotransferase (ALT) and alkaline phosphatase (ALP). Bar graph showing
ALT and ALP levels in serum obtained from mice vaccinated with vehicle only
(control), ES-exo or ES-exo/GM-CSF. (C-D) Kidney damage was assessed
by measuring the levels of blood urea nitrogen (BUN) and creatinine. Bar
graph showing the levels of BUN and creatinine in serum acquired from the
indicated mice. All of the data are presented as mean ± SD of measured
values with 4 mice in each group. n.s., not significant, ANOVA with Tukey’s
multiple comparison test.
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Figure 2.9. ES-exo/GM-CSF vaccination has no influence on blood cell
counts.
Male C57BL/6 mice were immunized twice with vehicle only (control), ESexo or ES-exo/GM-CSF (days 0 and 7). At day 14, whole blood was collected
from each mouse and examined by complete blood count (CBC). Bar graph
showing the levels of different cell types in blood obtained from the indicated
mice. The data represent mean ± SD of cell numbers. (n = 4 per group, mean
± SD; n.s., not significant, ANOVA with Tukey’s multiple comparison test).
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7. Vaccination with ES-exo/GM-CSF induces tumor cell-specific Th1mediated cytokine response in CD8+ T cells.
We next determined the ability of CD8+ T cells from vaccinated mice to produce
effector cytokines required for effective anti-tumoral cytolytic activity. These
experiments were carried out by the laboratory of Dr. Kavitha Yaddanapudi. In
response to re-stimulation with LLC cell lysate, a significantly higher frequency
of IFN-- and TNF--producing CD8+ splenocytes were obtained from ESexo/GM-CSF- vaccinated mice when compared with the non-vaccinated control
and ES-exo-vaccinated mice (Figure 2.10). Importantly, analysis of the
phenotype of tumor-infiltrating immune cells supports the concept that
vaccination led to an immune-based suppression of tumor growth.
Using tumors isolated from unvaccinated, ES-exo- and ES-exo/GM-CSFvaccinated mice, we found substantial increases in IFN-- and TNF-producing CD8+ T cells only in mice vaccinated with exosomes prepared from
GM-CSF-expressing ESCs in response to re-stimulation with LLC lysate
(Figure 2.11).
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Figure 2.10. ESC-derived exosome vaccination induces Th1-mediated
cytokine responses in splenic CD8+ T cells.
C57BL/6 mice were immunized twice (days 0 and 7) with vehicle only
(control, 1 x PBS), ES-exo or ES-exo/GM-CSF. Ten days after the boost,
splenocytes from mice were stimulated with LLC lysate and surface
expression of CD3, CD8 and intracellular expression of cytokines and
analyzed by flow cytometry. (A) Dot plots showing IFN- expression in CD8+
T cells in splenocyte cultures obtained from the indicated mice. Numbers in
graphs represent the percentages of each subpopulation. (B, C) Bar graphs
showing percentages of CD8+IFN-+, and CD8+TNF-+ in splenocyte
cultures derived from control, ES-exo- or ES-exo/GM-CSF-vaccinated mice.
Results are expressed as percentages of total cells (n = 6 per group, mean
± SD, **, p<0.001; ***, p<0.0001; ANOVA with Tukey’s multiple comparison
test).
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Figure 2.11. Vaccination with ESC-derived exosomes promotes Th1mediated cytokine responses in intratumoral CD8+ T cells.
Following immunization with vehicle only (control), ES-exo or ES-exo/GMCSF twice (days 0 and 7), C57BL/6 mice were challenged with injection of
LLC (s.c.) on day 14. Tumor-infiltrating cells were collected 15–18 days later
and stimulated with LLC lysate (50 mg/ml) for 24 hours. Cells were then
restimulated for 6 hours with LLC lysate (50 mg/ml) in the presence of
Brefeldin A (1 µL/ml). Surface expression of CD8 and intracellular expression
of cytokines were evaluated by flow cytometry. The pan-hematopoietic
marker CD45 was used to identify intratumoral immune cells. (A) Dot plots
showing IFN- expression in CD45+CD3+CD8+ cells obtained from control,
ES-exo- or ES-exo/GM-CSF-vaccinated mice. Numbers in graphs represent
the percentages of each subpopulation. (B, C) Bar graphs showing
percentages of CD45+CD3+CD8+ IFN-+ (B) and CD45+CD3+CD8+ TNF-α+
(C) in tumors derived from the indicated mice. Results are demonstrated as
percentages of IFN-+ cells or TNF-α+ cells in CD45+CD3+CD8+ cells (n = 6
per group, mean ± SD, *, p<0.05 **, p<0.001; n.s., not significant, ANOVA
with Tukey’s multiple comparison test).
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8. Vaccination with GMCSF-expressing ESC-derived exosomes increases
the ratio of CD8+ T effector cells to Tregs in the tumor.
Our results so far suggest that ES-exo/GM-CSF vaccine-induced antitumor efficacy is reliant on CD8+ T effector cells. Therefore, Dr. Kavitha
Yaddanapudi’s group analyzed effects of our vaccination strategy on the
phenotype of tumor-infiltrating CD8+ T cells and Tregs, a prominent suppressor
subset that hamper anti-tumoral effector responses. Tumors from controls and
vaccinated mice (from the small numbers of ES-exo/GM-CSF-vaccinated mice
that did develop LLC lesions) were harvested and used to investigate the
subset profiles of tumor-infiltrating immune cells. Flow cytometry analysis
showed a significant decrease in the percentage of CD4+CD25+Foxp3+ Tregs in
tumor infiltrates from ES-exo/GM-CSF-vaccinated mice when compared with
non-vaccinated control and ES-exo-vaccinated mice (Figures 2.12A-B) and the
ratio of CD8+ T cells to Tregs was significantly increased in the tumor infiltrates
from ES-exo/GM-CSF-vaccinated mice (Figure 2.12C). Additionally, CD8+ cells
in the ES-exo/GM-CSF tumor infiltrates had significantly elevated expression
of the activation marker CD25 (Figure 2.12D).
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Figure 2.12. ES-exo/GM-CSF vaccination decreases T regulatory (Tregs)
cells and increases the ratio of effector CD8+ T cells to Tregs in the
tumors.
C57BL/6 mice were vaccinated twice (days 0 and 7) with vehicle only
(control), ES-exo or ES-exo/GM-CSF followed by s.c. inoculation of LLC on
day 14. Tumor-infiltrating cells were analyzed by flow cytometry 15–18 days
later using the pan-hematopoietic marker CD45 to distinguish tumorinfiltrating immune cells from tumor cells. (A) Dot plots showing the
percentages of Foxp3+ Tregs in tumor-infiltrating CD3+CD4+ cells obtained
from the indicated mice. Numbers in graphs are the percentages of each
subpopulation. (B) Bar graphs showing the percentages of Foxp3+ Tregs subpopulations in tumor-infiltrating CD3+CD4+ cells (n = 4 per group, mean ±
SD, *, p<0.05; ANOVA with Tukey’s multiple comparison test). (C) Dot graph
showing the ratio of CD8+Foxp3- to CD8-Foxp3+ cells in 1 of 2 representative
experiments (n = 4 per group, mean ± SD, *, p<0.05; ANOVA with Tukey’s
multiple comparison test). (D) ESC-derived exosome vaccination increases
the frequency of functional CD8+ T cells in tumors. Bar graph showing the
percentages of CD25+CD8+ in CD45+ tumor-infiltrating cells obtained from
control and ES-exo/GM-CSF-vaccinated mice. Results are expressed as
percentages of CD45+ cells. The data represent results from 2 independent
experiments with 3 mice/group. *, p<0.05; relative to control group; unpaired
t test. Error bars represent mean ± SD.
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9. ESC-derived exosome vaccination prevents the outgrowth of an
implanted mammary carcinoma.
To test the effectiveness of ES-exo/GM-CSF vaccine in targeting multiple
cancer types, an additional experiment was performed using the mammary
carcinoma cell line 4T1, which is syngeneic to the Balb/c mouse strain. Female
Balb/c mice were divided into vehicle control, ES-exo and ES-exo/GM-CSF
groups (10 per group) and vaccinated for two weeks (s.c. route). Following
vaccination, 4T1 cells (1 x 105) were subcutaneously injected (Figure 2.13A).
Tumor growth assessment by caliper measurement showed significantly lower
tumor progression in the ES-exo/GM-CSF group (Figure 2.13B). Using
splenocytes isolated from unvaccinated, ES-exo- and ES-exo/GM-CSFvaccinated mice, we found a significant increases in IFN--producing CD8+ T
cells in mice vaccinated with ES-exo/GM-CSF in response to re-stimulation with
4T1 lysate (Figure 2.13C, D).
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Figure 2.13. Vaccination with ES-exo/GM-CSF slows the outgrowth of
an implanted mammary carcinoma.
(A) Scheme of immunization. Female Balb/c mice were immunized twice
(days 0 and 7) with vehicle only (control), ES-exo or ES-exo/GM-CSF before
s.c. challenge with syngeneic 4T1 cells on day 14. (B) Tumor growth was
monitored by measuring tumor volumes. The data represent the average
tumor volumes of 20 mice/group. Error bars represent mean ± SD. (C, D)
ESC-derived

exosome

vaccination

induces Th1-mediated

cytokine

responses in splenic CD8+ T cells. Splenocytes from vaccinated and control
mice were co-cultured with 4T1 lysate (50 mg/ml) for 4 days before
restimulation for 6 hours with 4T1 lysate (50 mg/ml) in the presence of
Brefeldin A (1 µl/ml). After restimulation, surface expression of CD8 and
intracellular expression of IFN-g were evaluated by flow cytometry. (C) Dot
plots showing IFN- expression in CD8+ cells in splenocyte cultures
obtained from the indicated mice. Numbers in graphs represent the
percentages of each subpopulation. (D) The data shown in (C) are
summarized. Results are presented as percentages of IFN--positive cells
in CD8+ cells (n = 4 per group, mean ± SD, *, p<0.05; ANOVA with Tukey’s
multiple comparison test).
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DISCUSSION
Traditionally, among different approaches of treatment, vaccines are a very safe
and effective strategy to prevent infectious diseases. However, the utilization of
vaccination in cancer prevention is limited. The only verified prophylactic anticancer vaccination in clinics is the vaccine against human papilloma virus (HPV)
that causes the greatest risk for cervical cancer [105]. This is a conventional
vaccine based on hollow virus-like particles. Unfortunately, most types of
cancers are not induced by infection. The development of prophylactic vaccine
against non-infection related cancers is still at early stages.
Fetal tissues have been reported to prevent transplantable tumors in the
20th century [18]. In a previous study [29], ESCs along with a source of GMCSF have been shown to successfully block the outgrowth of implanted as well
as carcinogen-induced lung tumors in mice. To eliminate the risk of teratoma
formation induced by ESCs, we generated ESCs over-expressing GM-CSF and
isolated the exosomes from the cells as a vaccine against implanted lung
tumors in the present study (Figure 2.1). As the effectiveness of embryonic
materials in tumor prevention is likely to be attributed to their pluripotent
characteristics shared with cancer cells, we ensured that exogenous
expression of GM-CSF did not influence the pluripotency of the transfected ESD3 cells (Figure 2.3). Furthermore, the exosomes isolated from the ES-D3 cells
appear to possess high purity without detectable contamination from other
cellular constituents, such as cytoplasm and organelles (Figure 2.4).
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As a monomeric glycoprotein cytokine, GM-CSF functions to stimulate the
development

of

the

immune

system,

such

as

activation

of

immune/inflammatory cascades [37]. Earlier studies indicate that GM-CSF by
itself lack cancer prevention efficacy. In prophylactic setting, an ES cell vaccine
composed of irradiated allogeneic murine ESCs and GM-CSF-expressing
murine STO fibroblasts was very effective in preventing lung malignancies [29].
Interestingly, STO fibroblasts expressing GM-CSF failed to provide any
protection against the outgrowth of LLC tumors, suggesting that the observed
protection with this vaccine is not due to non-specific immune responses
evoked by GM-CSF [29]. Therefore, it is unlikely that GM-CSF molecules in the
exosomes in ES-exo/GM-SCF vaccine are solely responsible for anti-tumor
immunity.
In our research, exosomes isolated from ESCs expressing GM-CSF could
be used as a vaccine for the prevention of transplanted lung tumor outgrowth
compared with the exosomes isolated from vector control cells (Figure 2.6). In
those animals that did develop tumors, tumor growth was significantly slower
when compared to unvaccinated control animals and those vaccinated with the
exosomes from ESCs lacking GM-CSF expression. In the latter group of
animals, tumor outgrowth did not differ from that detected in unvaccinated mice.
These findings indicate that GM-CSF is a potent stimulator of immune
responses during vaccination, which is in agreement with earlier reports [29,
106]. Indeed, the immunostimulatory property of GM-CSF has been recently
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exploited by Bencherif et al. for amplification of immune responses in a
melanoma model [107].
In our experimental tumor model, ES-exo/GM-CSF combination vaccine
significantly increases the ratio of CD8+ T cells to Tregs and the percentages of
CD8+CD25+ and CD8+IFN-+ effector cells within the tumors, suggesting
effective vaccine-induced, tumor-reactive immune system priming. These
immunophenotyping data lend additional support to the tentative conclusion
that such vaccination might be a viable approach to the prevention of cancers
in humans. Interestingly, the majority of detected GM-CSF was located inside
exosomes (Figure 2.5). Therefore, as an effective immunogen, the immunologic
activation by GM-CSF likely arises from exosomal fusion with the plasma
membrane of antigen-presenting cells.
The underlying mechanisms of the cancer-preventive efficacy of ESexo/GM-CSF vaccination are not fully understood. It is highly likely that
exosome-based vaccine elicits similar immune responses as its intact cellbased counterpart [29]. Anti-tumor immunity evoked by ES-exo/GM-CSF
vaccination may be attributed to an increase in an effective repertoire of CD8+
cytotoxic T cells, enhanced infiltration of CD8+ T cells into the tumor
microenvironment, and decreased tumor suppressive Tregs in tumors.
Extracellular vesicles (EVs) range in size from 20 nm to 200 nm in diameter
[55]. Exosomes, a subtype of EVs, are membrane vesicles with variable size of
30–100 nm in diameter. In Figure 2.4A, TEM images revealed that the sizes of
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vesicles in our samples were consistent with those of exosomes reported
previously. Purity of exosomal preparations was further demonstrated by
western blot analysis (Figure 2.4B), indicating the predominant presence of
exosomes in our samples. Due to overlapping molecular markers between
exosomes and other types of EVs, we could not completely exclude the
possibility of small amounts of EVs other than exosomes existing in our
preparations [90]. Additional experimental approaches, such as immunogold
TEM staining [108] and nanoparticle tracking analysis [109], could be utilized
to further characterize exosomal preparations from ESCs.
Exosomes, initially defined as cell-derived nanovesicles, were first
described in 1946 when they were isolated from platelets [56]. Recently,
evidence has emerged that exosomes could stimulate immune responses in
cancer treatment [87]. The exosome-based anti-cancer therapies have high
stability, in vivo bioavailability, and an inherent ability to stimulate anti-tumor
immune responses. Exosomes do not endogenously replicate, as whole cells
do, and exosomes can be readily bioengineered to a clinical grade and scaled
up for dosing requirements [91]. The idea of using tumor-derived exosomes as
a vaccine has been proposed earlier [110], although this approach is
complicated by the fact that such preparations may also be strongly
immunosuppressive. Furthermore, tumor cells expressing GM-CSF have been
explored to serve as a therapeutic vaccine with variable success in certain
animal models [111, 112]. In pre-clinical studies, exosomes obtained from
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matured dendritic cells (DCs) express more abundant MHC-I and MHC-II
molecules as well as co-stimulatory molecules (e.g., CD40, CD80, and CD86)
and induce potent antigen-specific anti-tumor T effector responses shown by
cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells both in vitro and in
vivo [71, 113, 114]. Similarly, the exosomes isolated from ESCs comprises
stable vesicles harboring protein contents that can be tailor-manufactured from
human cell lines in clinical grade (cGMP) quality [91]. Furthermore, ES-derived
exosomes can be produced in large quantities and cryo-preserved for more
than 6 months at −80 °C with their functional activity intact [103].
As a promising biological agent to prevent the outgrowth of lung cancer,
exosomes from ES-D3 cells expressing GM-CSF need to exhibit limited toxic
effects associated with the vaccination. Usually, the side effects of a biological
immune modulator or biological agent are different from conventional drugs
[115], and they are always linked to the biological effects induced by the agent.
There are five types of reactions of the adverse side-effects from biological
agents, including cytokine related syndrome, immediate and delayed
hypersensitivity reactions, immune imbalance syndrome, cross-reactions on
different tissues and non-immunological side-effects [116]. Particularly, these
reactions can be partially reflected from biological evaluations, such as CBC,
liver and kidney functions. Indeed, we did not observe any significant changes
in biological functional parameters between vaccinated and unvaccinated
animals, indicating that ES-exo/GM-CSF is a safe vaccination strategy without
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detectable side effects (Figure 2.7-9).
In our studies, ES-exo/GM-CSF immunization elicited immunologic
rejection of transplantable tumors (Figure 2.6). This raised a concern that the
vaccination strategy might have deleterious effects on fertility of vaccinated
female mice, as embryos could be eliminated by the immunity generation by
vaccine. As shown in Figure 2.7, ES-exo/GM-CSF vaccine exerted little
influence on the fertility of female mice. This could be explained by the
difference in antigen repertoires between mouse embryos and exosomes from
ESCs. As a result, vaccination with ES-exo/GM-CSF confers limited crossimmunity to embryos. In addition, maternal immune tolerance, the immune
tolerance towards the semi-allogeneic conceptus during pregnancy, is also
involved in protecting embryos from being rejected. Emerging evidence indicate
that a number of immunosuppressive factors produced by placenta are crucial
for maternal-fetal tolerance. Among them, placenta-derived exosomes bearing
human ligands of activating NK cell receptor NKG2D have been found to
promote the fetal immune escape by decreasing the cognate receptor
expression in a variety of immune cells [117].
The effects of aging on the immune system are well documented, as the
age of patients has great impacts on the immune responses and the outcomes
of treatment against lung cancer [118, 119]. Consequently, elderly lung cancer
patients generally do not respond to immunotherapy as well as younger
patients. In our study, we investigated the cancer prevention efficacy of
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exosome-based vaccine in mice at young age. In the future, animals with
different ages will be studied to evaluate how aging might influence the
vaccination efficacy of ES-exo-GM-CSF.
Finally, a recent publication shows that human and murine induced
pluripotent stem cells (iPSCs) express tumor-associated antigens, and that
irradiated autologous iPSCs, in a prophylactic setting, prevent tumor growth in
syngeneic murine breast cancer, mesothelioma, and melanoma models [30].
This study provides further support to our vaccination strategy utilizing
exosomes from GM-CSF-expressing ES-D3 cells as an effective immunepreventive lung cancer vaccine.
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CHAPTER III
MURINE ESC-DERIVED EXOSOMES FUNCTION AS A CELL-FREE
VACCINE AGAINST METASTASIZED LUNG CANCER

INTRODUCTION
It is well established that the immune system plays an essential role in lung
cancer therapy. Lung cancer cells are known to elicit suppressive immune
response by releasing cytokines such as interleukin 10 (IL-10) and transforming
growth factor β (TGF-β) [120]. In the tumor microenvironment, tumor cells also
express regulatory molecules to increase tumor-suppressive immune cell
populations, such as T regulatory cells (Tregs), and enable tumors to escape
from the immune system [121]. Immunotherapeutic strategies are generally
considered to display less unwanted toxicity compared with other types of
cancer treatment. The development of anti-cancer immunotherapy is
progressing in antigen-specific or antigen-nonspecific branches. Currently, the
most promising immune therapy is the immune checkpoint inhibitors by
blocking programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte
antigen 4 (CTLA-4) [122]. However, neoplastic cells are capable of escaping
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from immune surveillance through the inhibitory feedback loops, including the
PD-1 pathway. Particularly, the efficacy of checkpoint inhibitors to suppress lung
cancer, especially advanced or metastatic non-small cell lung cancer (NSCLC)
is modest [123].
A prophylactic cancer vaccine is a promising choice to reduce pulmonary
malignancy. The majority of cancer vaccines under development usually need
robust adjuvants to enhance the immune response because most of the tumor
antigens targeted in vaccines are identical to “self“ antigens [124]. However, the
efficacy of a lung cancer vaccine will be markedly increased if the vaccine
targets multiple “non-self” antigens presented only by lung tumors. Emerging
evidence has demonstrated that tumor cells and embryonic stem cells (ESCs)
share common antigens that are considered as “non-self” antigens, because
they are not expressed in normal adult tissues [18]. Based on the antigenic
similarity between malignant cells and ESCs, researchers have developed an
prophylactic lung cancer vaccine composed of irradiated, intact murine ESCs
and

murine

fibroblasts

expressing

the

immunostimulatory

adjuvant

granulocyte-macrophage colony stimulating factor (GM-CSF) [29]. In support
of cancer prevention capability of ESCs, a recent study has demonstrated that
irradiated, induced pluripotent stem cells (iPSCs) along with the adjuvant CpG
function as a tumor vaccine to elicit an anti-tumor response against
transplanted breast cancer, mesothelioma and melanoma [30].
Despite the promise of ESC-based vaccine to evoke anti-lung cancer
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immune responses, such a vaccine has two obvious challenges to overcome
for human application, First, the administration of intact ESCs, albeit irradiated,
raises the risk of embryoma/teratoma formation. Furthermore, it is
unnecessarily complicated to use fibroblasts as a source for the adjuvant GMCSF. To overcome these hurdles, we have developed an alternative
prophylactic vaccine comprised of exosomes from murine ESCs engineered to
produce GM-CSF (ESC-exo/GM-CSF). This self-contained, relatively stable
exosome-based vaccine significantly slowed or blocked the outgrowth of
subcutaneously implanted lung tumors (Figure 2. 6).
Metastasis results from the tumor cells on primary sites migrating to distant
organs. The process of metastasis includes cancer cell proliferation,
angiogenesis, cell adhesion, migration, and invasion into the surrounding tissue
[125]. The prognosis of cancer patients decreases dramatically once
metastasis happens [126]. Despite ongoing progress in diagnosis and patient
care, metastasis is still the principal cause of mortality from neoplastic diseases.
Lung metastasis occurs when malignant cells originating in another organ of
the body migrate to and establish in the lung. Chemotherapy is the most
commonly used therapy for lung metastasis with modest efficacy [127].
Therefore, if malignant cells metastasizing to the lung could be recognized by
the immune system and eliminated before their establishment and growth in the
lung, it would have promising application in clinics.
In this study, we show that ES-exo/GM-CSF vaccination effectively
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prevents the outgrowth of metastasized lung tumors in mice. Notably, the antitumor efficacy of this vaccination strategy is associated with reduced tumorpromoting immune cells and increased tumor-suppressing immune cells in lung
metastases. Overall, our research provides a strategy for developing a cell-free
preventative vaccine against metastasized lung tumors.
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MATERIALS AND METHODS
1. Mice
Female C57BL/6 mice (8 weeks of age) were purchase from Jackson
Laboratory (Bar Harbor, ME) and housed at the University of Louisville
Research Resources Facilities (RRF) under standard conditions. Mice were
handled in accordance with the American Association for the Accreditation of
Laboratory Animal Care (AAALC) guidelines and the "Guide for the Care and
Use of Laboratory Animals" (Institute of Laboratory Animal Resources, National
Research Council, National Academy Press, 1996). The mouse study was
approved by the Institutional Animal Care and Use Committee (IACUC) of the
University of Louisville (protocol number: 18301).
2. Vaccination and tumor challenge
Exosomes from ES-D3 cells were acquired as described in “MATERIALS AND
METHODS” section of Chapter 2. Female C57BL/6 mice (8 weeks of age) were
immunized twice (days 0 and 7) with vehicle only (1 x PBS), 225 µg exosomes
isolated from ES-D3 cells expressing the empty vector (ES-Exo) or 225 µg
exosomes isolated from ES-D3 cells stably-expressing GM-CSF (ES-Exo/GMCSF). Exosomes were injected subcutaneously (s.c.) in the right flank of mice.
Following vaccination, mice were challenged with LLC cells (0.15 ᵡ 106) by tail
vein injection on day 14. Immuno-analysis of splenocytes and tumor-infiltrating
lymphocytes were carried out 5 weeks following LLC cell challenge. Lung
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tumorigenesis was examined 6 or 7 weeks after LLC cell injection.
3. Histological analysis of lung tissues
Lung tissue sections were prepared as previously described with some
modifications [128]. Briefly, lung tissues were fixed in 10% neutral phosphate
buffered formalin for 24 hours at room temperature. After paraffin processing
(TEK VIP; Sakura Finetek; Torrance, CA) and embedding (EG1160; Leica
Biosystems; Buffalo Grove, IL), paraffin microtomy (RM2135; Leica Biosystems)
was performed at 5 microns thickness of slide for each section. 3 sections were
processed with 50 microns between each. For each biopsy core, three
consecutive sections are placed on 3 slides (total of 9 sections per lung tissue)
to assure detection of tumorigenesis in a whole lung. Slides of sections were
deparaffinized and rehydrated in xylene, ethanol and deionized water. Slides
were stained in hematoxylin (95057-844; VWR; Radnor, PA). After rinsing with
deionized water, the slides were stained by eosin (HT110232; Thermo Fisher)
and dehydrated in ethanol and xylene. Coverslips were mounted on slides by
xylene-based permountTM mounting medium (SP15-500; Thermo Fisher;
Waltham, MA). Finally, the slides were dried overnight in a chemical hood. The
slides were scanned by Aperio Imagescope (Leica Biosystems) and analyzed
with the software (version 12.3.3).
4. Antibodies for immune-analysis
Antibodies used for evaluating splenocytes and tumor-infiltrating lymphocytes
80

were: anti- CD3 mAb (clone 17A2, 100222); anti-CD4 mAb (clone GK1.5;
100406); anti-CD8 mAb (clone 53-6.7; 100712); anti-CD11b mAb (clone M1/70;
101228); anti-Ly6C mAb (clone HK1.4; 128006); anti-Ly6G mAb (clone 1A8;
127608); anti-CD16/CD32 mAb (clone 2.4G2; 101320) from Biolegend (San
Diego; CA), anti-CD44 mAb

(clone IM7; 17-0441-82); anti-CD25 mAb

(clone PC61.5; 45-0251-82) from (Thermo Fisher), anti-CD62L mAb (clone
MEL-14; 553152; BD Biosciences; San Jose, CA).
5. Immuno-analysis of splenocytes
Five weeks following tail vein injection of LLC cells into female C57BL/6 mice,
spleens were resected and splenocytes were acquired. Single splenocyte
suspensions were stained with the indicated antibodies for 30 minutes after
blocking with CD16/CD32 antibody for 15 minutes at 4 °C. After washing, cell
surface and intracellularly stained cells were analyzed on a FACSCalibur
(Becton Dickinson; Franklin Lakes, NJ) and results were analyzed using FlowJo
software (TreeStar, Inc., Ashland, OR).
6. Immuno-analysis of tumor-infiltrating immune cells
Vaccinated and control mice with LLC tumors metastasized to lungs were
euthanized 35 days after tumor challenge. Lungs were resected and
metastasized LLC tumors were dissected and chopped into small pieces before
incubation with a mixture of enzymes dissolved in HBSS, including collagenase
type IV (400 U/ml; C9891; Sigma-Aldrich; St. Louis, MO), hyaluronidase (0.025
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mg/ml; H6254; Sigma-Aldrich) and DNase I (0.01 mg/ml; D5025; Sigma-Aldrich)
for 2 hours at 37°C with occasional shaking. The resultant cells were washed
and passed through a Ficoll gradient (17144002; GE Healthcare; Chicago, IL)
to eliminate dead cells. Tumor-infiltrating lymphocytes (TILs) were then
analyzed by flow cytometry for the expression of markers for different immune
cells. Anti-CD45 antibody was used to selectively exclude CD45 − tumor cells
from analysis so that only CD45+ immune cells were evaluated. The same
number of cells (based on side-scatter and forward-scatter analyses) was
acquired in all samples. Respective antibodies specific for the makers were
used to quantitate the abundance of different immune cell types. T regulatory
cells (Tregs; Foxp3+) were analyzed using the anti-mouse Foxp3 staining kit (005523-00; Thermo Fisher).
7. Intracellular cytokine staining
To evaluate TNF-α and IFN-γ production, TILs were harvested and
restimulated for 6 h with the LLC lysate (50 μg/ml) in the presence of Golgiplug
(555029; BD Biosciences) at a concentration of 1 μl/ml of culture medium. After
restimulation, cells were harvested, Fc receptors were blocked using antiCD16/CD32 antibodies, and cells were stained for surface expression of CD8
and intracellular expression of cytokines using Cytofix/Cytoperm kit (555029;
BD biosciences) according to the manufacturer’s instructions and analyzed by
flow cytometry.
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8. Statistical analysis
The statistical analysis was carried out using StatView version 5.0.1 software
(Windows version; SAS Institute, Cary, NC) or GraphPad Prism 5.0 software
(GraphPad Prisim Software, Inc., La Jolla, CA). Comparisons between
experimental groups were conducted using Student’s t test or one-way analysis
of variance (ANOVA) where P value < 0.05 was considered significant.
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RESULTS
1. Vaccination with ES-exo/GM-CSF inhibits metastasized lung tumor
growth
Metastatic lung cancer is one of the leading causes of death worldwide. As a
low immunogenic cancer, it is resistant to the surveillance of the immune
system [129, 130]. In our earlier studies, a prophylactic vaccine comprised of
exosomes derived from murine ESCs engineered to produce GM-CSF (ESexo/GM-CSF) significantly slowed or blocked the outgrowth of subcutaneously
implanted LLC (Figure 2.6). To evaluate the efficacy of ES-exo/GM-CSF
vaccine in preventing metastasized lung tumor development, a mouse model
of experimental pulmonary metastasis was investigated., In this model, tumor
cells are first injected into the tail vein then reach the lung through blood
circulation, where tumors are established [131].
Following a standard immunization timing regimen, C57BL/6 mice were
vaccinated at day 0 and again on day 7 with 1 x PBS (vehicle control),
exosomes alone (ES-exo) or GM-CSF-containing exosomes (ES-exo/GM-CSF)
through subcutaneous (s.c.). injection (Figure 3.1A). Mice were then challenged
with tail vein inoculation of LLC cells (0.15 x 106) at day 14. In this experimental
model, LLC tumors were established in the lung 5 weeks following LLC
challenge.
To rigorously examine the vaccination efficacy of ES-exo/GM-CSF on
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metastasized LLC tumors, we carried out two independent experiments to
examine the status of lung tumors generated by metastasized LLC cells 6
weeks or 7 weeks following initial LLC cell administration. Immediately after
collecting lung tissues from the mice in 3 experimental groups, we first counted
the numbers of tumor nodules on lung surface [132], as a lung tumor nodule is
defined as a discrete, well-defined, rounded opacity that is completely
surrounded by lung tissue (Figure 3.1B). The results of lungs acquired 6 weeks
after LLC inoculation are similar to those obtained 7 weeks post LLC injection
(Figure 3.1C). Examination of resected lungs revealed that the numbers of lung
tumor nodules in mice vaccinated with ES-exo/GM-CSF were significantly
smaller than those in mice injected with vehicle control. The majority of PBSadministered mouse lungs had surface tumors (8 out of 9 for 6-week group; 10
out of 11 for 7-week group) with an average of about 3.5 lesions for each mouse.
In contrast, mice vaccinated with ES-exo/GM-CSF only had an average of 0.5
lung tumors/mouse (6-week group) or 1.4 lung tumors/mouse (7-week group),
indicating that immunization with ES-exo/GM-CSF inhibited the metastasized
lung tumor development. The average tumor nodule number in mice vaccinated
with ES-exo was higher compared with ES-exo/GM-CSF-immunized mice, but
the difference was not significant due to variations among the mice in each
group.
To further investigate the efficacy of this vaccination strategy, total lung
tumor mass of metastasized LLC was evaluated by a histological approach.
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Serial sections were produced from each lung resected from the mice, stained
with hematoxylin and eosin (H&E) and analyzed by measuring the tumor lesion
areas in each lung tissue (Figure 3.1D). Typical lung sections from mice showed
a striking difference between PBS-inoculated mice versus those receiving ESexo/GM-CSF vaccination. Numerous large tumor lesions were detected in nonvaccinated control mouse lung sections, whereas vaccinated animals were
almost absent of any detectable lesions (Figure 3.1D). The tumor burden was
calculated as the percentage of lung area occupied by tumor lesions in each
slide. As shown in Figure 3.1 E, ES-exo/GM-CSF-vaccinated mice had a
significantly smaller percentage of tumor-bearing lung area compared with the
mice in unvaccinated control (1x PBS) group or the mice vaccinated with
exosomes without GM-CSF (ES-exo). Absence of metastasized lung tumors in
mice immunized with ES-exo/GM-CSF provides evidence that ES-exo/GMCSF suppresses the development of metastasized lung malignancy, which is in
agreement with our earlier studies with subcutaneously implanted LLC tumors
(Figure 2.6).
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Figure 3.1. ES-exo/GM-CSF vaccination inhibits the outgrowth of
metastasized lung tumors.
(A) The scheme of vaccination is depicted. Female C57BL/6 mice were
immunized twice (Days 0 and 7) with vehicle control (1 x PBS), exosomes
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isolated from vector control ES-D3 cells (ES-exo) or exosomes isolated from
GM-CSF-expressing ES-D3 cells (ES-exo/GM-CSF) prior to tail vein
6

injection with LLC cells (0.15 ᵡ 10 ) on Day 14. Lung tumor development was
examined 6 weeks or 7 weeks after LLC injection. (B) Representative
images of lungs resected from euthanized mice. Surface tumor nodules
were indicated by arrows. Scale bar, 0.5 cm. (C) Surface tumor nodules of
resected lungs were enumerated by inspection. The data are presented as
a dot graph of the number of surface tumor nodules of lungs. In the
experiments carried out 6 weeks after LLC injection, 10 mice in each group.
In the studies performed 7 weeks following LLC challenge, 11 mice in control
group, 9 mice in ES-exo group and 10 mice in ES-exo/GM-CSF group. *, p
< 0.05; **, p < 0.01; ANOVA with Tukey’s multiple comparison test. (D) The
histological sections of resected lungs were examined by H&E staining.
Representative images of lung sections are shown (magnification: x 200).
Lesions on lung sections are indicted by arrows. Scale bar, 500 µM. (E) The
tumor lesion areas of each lung tissue sections were measured. The
percentage of total lung area taken up by lung tissues was quantified from
measurements on H&E sections of resected lungs from animals in each
group. For each lung, the average value of 3 sections with 50 microns apart
was calculated. *, p < 0.05; **, p < 0.01; ANOVA with Tukey’s multiple
comparison test.
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2. ES-exo/GM-CSF vaccination decreases T regulatory cells (Tregs) in lung
metastases.
It is generally believed that immune cells infiltrating into tumor tissues play
essential roles in tumor development and progression [133]. Importantly, tumorinfiltrating immune cells are involved in cancer prevention efficacy of a vaccine
composed of intact ESCs and STO fibroblasts expressing GM-CSF [29]. As
shown in Figure 3.1, a limited number of mice vaccinated with ES-exo/GM-CSF
did develop LLC lesions in the lung. To elucidate the underlying mechanisms of
the immunity against metastasized lung cancer by ES-exo/GM-CSF
vaccination, Dr. Kavitha Yaddanapudi’s laboratory analyzed the phenotypes of
tumor-infiltrating immune cells by examining the expression of different immune
cell markers. Pan-leukocyte marker CD45 was studied to ensure that only
CD45+ immune cells in tumor infiltrates were examined.
T cells are known to play an important role in immune responses arising
during malignancy. Among them, cytotoxic T cells (Tc) have the capability to kill
a variety of neoplastic cells, whereas immunosuppressive T regulatory cells
(Tregs) contribute to the development and progression of many cancer types by
reducing effector cell responses [134, 135]. Therefore, we first analyzed the
effects of our vaccination strategy on tumor-infiltrating Tc and Tregs. As shown in
Figures 3.2A and 3.2B, immunization with ES-exo/GM-CSF failed to affect
intratumor CD8+ Tc levels. However, flow cytometry analysis revealed a
significant decrease in the percentage of Foxp3+ Tregs in CD4+ T helper cells of
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tumor infiltrates from ES-exo/GM-CSF-vaccinated mice when compared with
non-vaccinated control mice (Figures 3.2C-D).
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Figure 3.2. Vaccination with ES-exo/GM-CSF decreases T regulatory
cells (Tregs) in metastasized lung tumors.
Female C57BL/6 mice were vaccinated twice (days 0 and 7) with 1 x PBS
(control) or ES-exo/GM-CSF prior to tail vein injection with LLC on day 14.
Five weeks following LLC challenge, lung tumors were resected, digested
by enzymes, and tumor-infiltrating cells were harvested and analyzed by
flow cytometry. The pan-hematopoietic marker CD45 was used to identify
intratumoral immune cells. (A) The presence of tumor-infiltrating cytotoxic T
cells (Tc) was examined and the percentages of CD8+ Tc cells in CD3+ T cell
population were determined. (B) Bar graphs showing average of
percentages of tumor-infiltrating CD8+ Tc cells in CD3+ T cells. Four mice in
control group, and six mice in ES-exo/GM-CSF group. Mean ± SD, n.s., not
significant; ANOVA with Tukey’s multiple comparison test. (C) Tumorinfiltrating Foxp3+ Tregs in CD3+ CD4+ T cells obtained from control and ESexo/GM-CSF-vaccinated mice were evaluated. Numbers in the plots
represent the percentages of subpopulations. (D) Summary of the data
shown in (C). (n=4 in control group, n=6 in ES-exo/GM-CSF group; mean ±
SD, *, p < 0.05; ANOVA with Tukey’s multiple comparison test).
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3.

Vaccination

with ES-exo/GM-CSF suppresses

tumor-infiltrating

myeloid derived suppressor cells (MDSCs).
In addition to Tregs, myeloid-derived suppressor cells (MDSCs) are another
prominent suppressor class hampering anti-tumoral effector responses [136].
To elucidate the immunomodulatory influences of ES-exo/GM-CSF vaccination,
we first evaluated the abundance of CD11b+ immune cells in lung metastases
with the help of Dr. Kavitha Yaddanapudi. The presence of CD11b+ MDSC in
tumor-infiltrating non-T (CD3-) and non-B (CD19-) immune cells was
significantly reduced from 80.7% to 34.9% (Figure 3.3A). As a heterogeneous
population of immature myeloid cells, MDSCs are composed of the monocytic
subset (M-MDSCs) and granulocytic subset (G-MDSCs), both of which display
immune-suppressive capability to promote tumor development. To further
explore the effects of ES-exo/GM-CSF vaccination on intratumoral MDSCs, we
examined the presence of MDSC subsets in metastasized lung tumors. As
shown in Figure 3.3C, the percentage of tumor-infiltrating Gr-1+ G-MDSCs in
CD11b+ non-T and non-B immune cells was significantly decreased from 49.5%
to 15.5% in mice vaccinated with ES-exo/GM-CSF and challenged with LLC
cells when compared with non-vaccinated, LLC challenged control mice. In
contrast, ES-exo/GM-CSF vaccination did not reduce the percentage of Gr-1low
M-MDSCs in lung metastases, suggesting that different subclasses of
intratumoral MDSCs play distinct role in anti-tumor efficacy of ES-exo/GM-CSF
vaccination.
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Figure 3.3. Vaccination with ES-exo/GM-CSF suppresses tumorinfiltrating MDSCs
Female C57BL/6 mice were vaccinated with 1 x PBS or ES-exo/GM-CSF
twice (days 0 and 7) and challenged by tail vein inoculation LLC one week
later. Myeloid derived suppressor cells (MDSCs) infiltrating into lung tumors
were examined 5 weeks after LLC injection. Intratumoral immune cells were
identified by CD45, a pan-hematopoietic marker. (A) Dot plots showing the
abundance of CD11b+ cells in tumor-infiltrating non-T (CD3-) and non-B
(CD19-) immune cells obtained from control and ES-exo/GM-CSFvaccinated mice. The percentages of the individual subpopulation are
shown. (B) The data shown in (A) are summarized with 4 mice in control
group, 6 mice in ES-exo/GM-CSF group. Mean ± SD, **, p < 0.001; ANOVA
with Tukey’s multiple comparison test. (C) Gr-1high granulocytic myeloid
derived suppressor cells (G-MDSCs) and Gr-1low Monocytic myeloid derived
suppressor cells (M-MDSCs) in CD11b+ populations shown in (A) were
examined. The percentages of each subpopulation are indicated in the
graphs. (D-E) Bar graphs show the summarized data presented in (C). (n =
4 in control group, n = 6 in ES-exo/GM-CSF group; mean ± SD; ***, p <
0.0001; n.s., not significant; ANOVA with Tukey’s multiple comparison test).
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4.

Vaccination

with ES-exo/GM-CSF reduces the

percentage

of

macrophages in metastasized lung tumors.
As

an

integral

component

of

tumor

microenvironment,

intratumoral

macrophages are associated with initiation as well as progression of various
malignancies [137]. The influence of vaccination with ES-exo/GM-CSF on
tumor-infiltrating macrophages was investigated by Dr. Kavitha Yaddanapudi.
Previous studies demonstrate that the cell surface protein F4-80 is a major
marker of murine macrophages [138]. As shown in Figure 3.4A, the abundance
of F4-80+Gr-1- macrophages in intratumoral CD11b+ non-T and non-B immune
cells was significantly decreased from 15.8% to 3.06% in ES-exo/GM-CSFvaccinated mice compared with non-vaccinated mice inoculated with the
vehicle control. The CX3CR1+ subpopulation of macrophages has been shown
to play a central role in lung cancer growth and metastasis via CX3CR1
signaling [139]. However, the percentage of tumor-infiltrating CX3CR1+
macrophages was not significantly influenced by vaccination with ES-exo/GMCSF (Figure 3.4D), suggesting that the involvement of distinct subpopulations
of intratumoral macrophages in the immune responses to ES-exo/GM-CSF
vaccination is different.
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Figure 3.4. Vaccination with ES-exo/GM-CSF reduces tumor-infiltrating
macrophages.
The vehicle control (1 x PBS) or ES-exo/GM-CSF was injected into female
C57BL/6 mice twice with 7 days apart, followed by tail vein inoculation of
LLC 7 days later. The presence of tumor-infiltrating macrophages was
analyzed by flow cytometry 5 weeks after LLC injection. CD45, as a panhematopoietic marker, was analyzed to evaluate intratumoral immune cells.
(A) The percentages of F4-80+GR-1- macrophages in intratumoral non-T
(CD3-) and non-B (CD19-) immune cells from control and ES-exo/GM-CSFvaccinated mice are shown. Numbers in the plots represent the percentages
of each subpopulation. (B) Bar graphs showing the average of percentages
of F4-80+GR-1- macrophages obtained from control and ES-exo/GM-CSFvaccinated mice (n=4 in control group, n=6 in ES-exo/GM-CSF group; mean
± SD, **, p < 0.001; ANOVA with Tukey’s multiple comparison test). (C) Dot
plots representing the abundance of CX3CR1+ macrophage subset in
tumor-infiltrating general macrophage populations shown in (A). The
percentages of the individual subpopulation are indicated. (D) The data
shown in (C) are summarized with 4 mice in control group, 6 mice in ESexo/GM-CSF group. Mean ± SD, n.s., not significant; ANOVA with Tukey’s
multiple comparison test.
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5. ES-exo/GM-CSF vaccination promotes intratumoral B cell populations.
Emerging evidence has demonstrated that tumor-infiltrating B cells play a
critical role in tumor development at all stages of lung tumorigenesis [140]. To
test the effect of ES-exo/GM-CSF vaccination on the levels of B cell populations
in metastasized lung tumors, Dr. Kavitha Yaddanapudi’s group evaluated the
presence of CD19+ B cells in intratumoral cells positive for CD45. As shown in
Figure 3.5, the percentage of CD19+ B cells in tumor-infiltrating CD45+ immune
cells was significantly increased from 11.1% to 38.1% in mice vaccinated with
ES-exo/GM-CSF and challenged with LLC cells than their non-vaccinated
control counterparts.
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Figure 3.5. ES-exo/GM-CSF vaccination promotes tumor-infiltrating B
cells against lung metastases.
Female C57BL/6 mice were vaccinated twice (days 0 and 7) with vehicle
only (1 x PBS) or ES-exo/GM-CSF followed by LLC challenge through tail
vein 7 days later. After 5 weeks, cells infiltrating into lung metastases were
harvested and evaluated using the pan-hematopoietic marker CD45 to
distinguish tumor-infiltrating immune cells from malignant cells by a flow
cytometry analysis. (A) Dot plots showing the percentages of CD19+ B cells
in CD45+ intratumoral cells obtained from control and ES-exo/GM-CSFvaccinated mice. Numbers in the dot plots are the percentages of each
subpopulation. (B) Bar graphs showing average of percentages of CD19+ B
cells in tumor-infiltrating CD45+ cells acquired from control and ES-exo/GMCSF-vaccinated mice with 4 mice in control group, 6 mice in ES-exo/GMCSF group. Mean ± SD, **, p < 0.001; ANOVA with Tukey’s multiple
comparison test.
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6. Intratumoral Th1 and Th17 effector cells are not affected by ES-exo/GMCSF vaccination.
It is well known that tumor-infiltrating CD4+ effector T cells play critical roles in
malignancies. Among them, Th1 and Th17 subsets of CD4 + cells are deeply
associated with pulmonary tumorigenesis [141, 142]. To investigate whether
ES-exo/GM-CSF vaccination affects the presence of Th1 or Th17 populations
in metastasized lung tumors, Dr. Kavitha Yaddanapudi’s laboratory helped us
to examine CX3CR1+ Th1 and RORT+ Th17 cells in tumor-infiltrating T cells
positive for CD4. As shown in Figure 3.6, the percentages of intratumoral
CX3CR1+ Th1 and RORT+ Th17 cells CD4+ effector T cells were not
significantly altered in mice vaccinated with ES-exo/GM-CSF and challenged
with LLC cells compared with non-vaccinated control mice.
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Figure 3.6. The levels of Th1 and Th17 effector cells in lung metastases
are not affected by ES-exo/GM-CSF vaccination.
Female C57BL/6 mice were vaccinated with 1 x PBS or ES-exo/GM-CSF
twice (days 0 and 7). Seven days later, mice were injected with LLC cells
through tail vein. Intratumoral CD4+ Th1 and CD4+ Th17 cells were
examined 5 weeks following LLC inoculation. The pan-hematopoietic
marker CD45 was evaluated to distinguish immune cells from cancer cells
in lung metastases. (A) The presence of TBET+ Th1 in tumor-infiltrating
CD3+CD4+ effector T cells was examined by flow cytometry. Numbers
shown in plots are the percentage of each subpopulation. (B) Bar graphs
showing average of percentages of TBET+ Th1 cells in tumor-infiltrating
CD3+CD4+ cells acquired from control and ES-exo/GM-CSF-vaccinated
mice with 4 mice in control group, 6 in ES-exo/GM-CSF group. Mean ± SD,
n.s., not significant; ANOVA with Tukey’s multiple comparison test. (C)
Intratumoral RORT+ Th17 cells in CD3+CD4+ effector T cells obtained from
control and ES-exo/GM-CSF-vaccinated mice were evaluated. Numbers in
the plots are the percentages of subpopulations. (D) The data shown in (C)
are summarized. (n = 4 in control group, n = 6 in ES-exo/GM-CSF group;
mean ± SD, n.s., not significant; ANOVA with Tukey’s multiple comparison
test).
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7. Vaccination with ES-exo/GM-CSF induces a tumor cell-specific
cytokine response in tumor-infiltrating CD8+ T cells.
Since cytolytic cytokines produced by tumor-infiltrating CD8+ T cells are known
to contribute to the anti-tumor function of CD8+ T cells [143], With the help of
Dr. Kavitha Yaddanapudi’s group, we investigated the capability of intratumoral
CD8+ T cells from vaccinated mice to generate cytokines required for cytotoxic
activity against tumors. Tumor-infiltrating immune cells were acquired from
metastasized lung tumors in mice immunized with ES-exo/GM-CSF or the
vehicle control. Following stimulation with LLC cell lysate, IFN- and TNF-
levels in intratumoral CD8+ T cells were evaluated. As shown in Figure 3.7, a
significantly higher percentage of IFN--producing CD8+ T cells were found in
lung metastases in ES-exo/GM-CSF-vaccinated mice than their nonvaccinated counterparts. However, the modest increase in IFN--producing
CD8+ T cells promoted by ES-exo/GM-CSF vaccination was not significant.
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Figure 3.7. Vaccination with ES-exo/GM-CSF promotes cytokine
production from CD8+ T cells.
Female C57BL/6 mice were immunized twice (days 0 and 7) with vehicle
control (1 x PBS) or ES-exo/GM-CSF prior to tail vein injection with LLC. 5
weeks after LLC challenge, lung tumors were resected, tumor-infiltrating
cells were harvested and stimulated with LLC cell lysate for 6 hours.
Intratumoral immune cells were identified by the pan-hematopoietic marker
CD45 and intracellular expression of IFN-γ and TNF-α was examined by
flow cytometry. (A) Dot plots showing IFN-γ expression in tumor-infiltrating
CD3+CD8+ T cells obtained from control and ES-exo/GM-CSF-vaccinated
mice. Numbers in plots represent the percentages of each subpopulation.
(B) The data shown in (A) are summarized with 4 mice in control group, 6
mice in ES-exo/GM-CSF group. Mean ± SD, **, p < 0.001; ANOVA with
Tukey’s multiple comparison test. (C) The presence of TNF-α+ cells in tumorinfiltrating CD45+CD3+CD8+ cells was examined by flow cytometry.
Numbers indicated in plots are the percentage of each subpopulation. (D)
Bar graphs showing average of percentages of TNF-α+ in intratumoral
CD3+CD8+ T cells derived from control and ES-exo/GM-CSF-vaccinated
mice. (n = 4 per group; mean ± SD; **, n.s., not significant; ANOVA with
Tukey’s multiple comparison test).
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DISSCUSION
The prevalence of pulmonary metastases from different primary tumors is
relatively high due to the abundant bloodstream in the lung capillary bed [144].
Although there are several therapeutic options available for lung metastases,
the overall outcome is still unsatisfactory. In this study, we investigated an
experimental metastasis model where syngeneic LLC cells were administered
directly into the bloodstream of wild-type C57BL/6 mice through tail vein
injection, primarily resulting in pulmonary metastases [145]. Specifically, we
examined the effects of a vaccine composed of exosomes from GM-CSFexpressing ES-D3 cells on metastasized lung malignancy. Our data provide
evidence that a vaccine derived from GM-CSF-expressing human ESCs could
potentially be used to prevent the development of lung metastases in the future.
In humans, metastasized lung malignancies are developed when cancer
spreads to lung from where it originates. The metastasis mouse model in our
study recapitulates the critical process of tumor cell extravasation from blood
vessels in target organs, but it lacks the process of tumor cell metastasizing
from primary tumor site and the generation of adhesion and traction forces
required for cell migration [146]. Future research is warranted to investigate the
efficacy of ES-exo/GM-CSF in tumor models more truthfully recapitulating the
process of metastasis in lung cancer patients.
Accumulating evidence indicate that stem-like cells, called cancer stem
cells (CSCs) and more differentiated trophoblast-like cells coexist within lung
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metastases. With self-renewal and differentiation capabilities similar to those of
normal stem cells, CSCs are a likely source of cancer metastases. [147].
Furthermore, the presence of CSCs is a particular challenge in treating
metastasized lung cancer because CSCs tend to be resistant to standard
chemotherapy and radiotherapy. If lung CSCs could be recognized and
eliminated by the immune system, the morbidity of cancer metastasis would
likely decrease. Earlier studies suggest that the efficacy of ESC vaccination is
associated with the immunity targeting CSCs [29]. In our study, vaccination with
exosomes derived from ESCs induced immune responses against initiation and
progression of lung metastases (Figure 3.1). It is conceivable that ES-exo/GMCSF vaccination triggers immune recognition and eradication of lung CSCs.
Future studies are needed to address whether lung CSCs are the targets for
this vaccination strategy against metastasized lung tumors.
Emerging evidence has demonstrated that tumor-infiltrating lymphocytes
(TILs) are deeply involved in metastasis of malignancy [133]. As ES-exo/GMCSF vaccination successfully blocked the outgrowth of metastasized lung
tumors (Figure 3.1), we evaluated the comprehensive profile of intratumoral
immune cells to elucidate the nature of immunity against lung metastases
evoked by ES-exo/GM-CSF vaccination. In our research, we first observed a
significant reduction in the presence of Tregs in lung metastases of
vaccinated/tumor-challenged mice compared with non-vaccinated/tumorchallenged control mice though Th17 cells which are relevant to suppress the
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Tregs differentiation were unchanged after immunization (Figure 3.2; 3.6). This
is consistent with the findings that increased Tregs population in metastasized
malignancy often correlates with an immunosuppressive phenotype and poor
patient prognosis [148]. Similarly, ES-exo-GM-CSF vaccination significantly
decreased the abundance of MDSCs, particularly G-MDSC subset, in TILs
(Figure 3.3). As a suppressor of T cell proliferation and activation, MDSCs
expansion in TILs is an obstacle in tumor immunotherapy. Furthermore, it has
been reported that the pulmonary G-MDSC infiltrates are dramatically
increased as the metastases form in the lungs to suppress the anti-tumor
immune response[149]. Therefore, the presence of two prominent suppressor
populations that hamper anti-tumoral effector responses, Tregs and MDSCs,
were suppressed by ES-exo/GM-CSF vaccination, which is correlated with the
effectiveness of this vaccine.
Tumor-associated macrophages are one of the major constituents that
promote tumor progression by inhibiting tumor cell apoptosis and producing
many pro-angiogenic factors [150]. Intratumoral macrophages have been
linked to poor clinical outcome in lung cancer patients [137, 151]. In our study,
percentage of F4/80+ macrophages in TILs was significantly decreased by
immunization of ES-exo/GM-CSF compared with the control group (Figure
3.4B). As one subtype of macrophages, CX3CR1+ macrophages are involved
in lung cancer growth and metastasis [139]. However, we failed to observe any
significant difference in CX3CR1+ populations between the mice in the
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vaccinated group and their counterparts in the control group (Figure 3.4D).
Like many other intratumoral immune cells, macrophages infiltrated into
tumors also display multifaceted activities to regulate tumor immunity, rather
than simply stimulating or hindering tumorigenesis and metastasis [152]. There
are two distinct subtypes of macrophages existing in tumor infiltrates: proinflammatory, anti-tumor M1 class and anti-inflammatory, pro-tumor M2 class.
In the majority of solid tumors, M2 macrophages are considered as the
dominant subtype, conferring an immunosuppressive microenvironment to
support malignancy progression. However, the composition of tumor-infiltrating
macrophages is heterogeneous and complicated, which is determined by the
cancer type, malignancy development stage, tumor size, as well as location of
cancer cells in malignant tissues [152]. Future studies will reveal the effects of
ES-exo-GM-CSF vaccination on the identity and heterogeneity of macrophages
in lung tumor metastasis.
It has been demonstrated that Th1 and Th17 subsets of CD4 + T cells are
involved in lung malignancy and metastasis [141, 142]. Th1 cells increase cellmediated immune responses by producing effector cytokines, including IFN-.
Th1 immunity contributes to activation of CD8+ T cells and IFN- expression in
CD4+ T cells [153]. As a subset of pro-inflammatory T helper cells, Th17 cells
are defined by their production of IL-17. The signals from Th17 cells are related
to inhibition of Treg differentiation [154]. In our study, there was no significant
change in the presence of Th1 and Th17 cells in pulmonary tumor infiltrates
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between mice immunized with ES-exo-GM-CSF and their non-vaccinated
counterparts (Figure 3.6), suggesting that this vaccination strategy elicits
immunity through mechanisms independent of Th1 and Th17.
CD8+ cytotoxic T cells are known to induce anti-tumor immunity by
producing cytolytic cytokines, such as IFN- and TNF- [155]. However,
cytokines released from tumor-infiltrating CD8+ T cells are one of the crucial
contributing factors in immune response against cancer cells [155]. ESexo/GM-CSF vaccination significantly boosted the frequency of IFN-producing CD8+ cytotoxic T cells in lung metastases (Figure 3.7), which is
consistent with the data acquired from subcutaneously injected lung tumors
(Figure 2.11). However, the levels of TNF--producing CD8+ cytotoxic T cells in
metastasized pulmonary malignancies were unaffected by ES-exo/GM-CSF
vaccination. In contrast, the levels of TNF--generating CD8+ cytotoxic T cells
in subcutaneously implanted lung tumors were markedly increased by ESexo/GM-CSF vaccination, suggesting that different tumor microenvironments
might determine the production of cytokines by CD8+ cytotoxic T cells.
In our studies, when tumor-infiltrating immune cells were acquired for
immunoanalysis, tumor metastases in the lungs of mice vaccinated with ESexo-GM-CSF were much smaller than those of non-vaccinated mice (Figure
3.1). The observed difference in intratumoral lymphocyte profiles between
vaccinated group and control group could be partially attributed to various
stages of lung metastases. More experiments are warranted to examine tumor108

infiltrating immune cells from lung metastases at similar stages in the future.
In summary, the protection against metastasized lung cancer afforded by
ES-exo/GM-CSF vaccination involves a number of immune response pathways.
Future studies will focus on elucidating how this vaccination strategy not only
promotes the effector function of the immune system but also suppresses
various immune evasion mechanisms conferred by developing lung
metastases, which is attributed to the robust efficacy against metastasized
pulmonary malignancies.
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CHAPTER IV

THE PLURIPOTENCY OF EMBRYONIC STEM CELLS IS ESSENTIAL FOR
CANCER-PREVENTION EFFICACY OF EMBRYONIC STEM CELL-BASED
VACCINE

INTRODUCTION
The association between embryonic materials and tumors has initiated many
research activities on exploring the therapeutic potential of embryonic stem
cells (ESCs) against cancer [26, 29]. In the 1960s, Triolo proposed a theory that
cancer originates from ESCs [84], indicating that cancer cells possess similar
characteristics as ESCs. It is well known that ESCs and tumor cells share some
antigens. Since 1960s, the antigen overlap between embryonic tissues and
neoplastic cells, such as carcinoembryonic antigen (CEA), prostate-specific
antigen (PSA), and cancer/testis antigen (CTA), has been extensively studied,
[18]. However, the full extent to which embryonic/cancer tissues overlap in
antigens remains unknown. Thus, understanding this overlap remains an area
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of ongoing research. It has been demonstrated that embryonic materials
possess immune regulatory activity to prevent cancers as a vaccination
strategy [26]. Exploiting the antigenic similarity between malignant cells and
ESCs, a recent study reports the development of an anti-lung cancer vaccine
based on allogeneic murine ESCs along with allogeneic murine fibroblasts
expressing granulocyte-macrophage colony stimulating factor (GM-CSF) as an
immunostimulatory adjuvant [26]. Another study provides support for this
strategy by demonstrating that irradiated, induced pluripotent stem cells (iPSCs)
function as a prophylactic vaccine against transplanted lung tumors [30].
Nevertheless, further research is needed to completely elucidate how the
similarity between cancer cells and ESCs contributes to the immunity of ESCs
against cancer.
The pluripotency of ESCs is one of the most specialized properties shared
with cancer stem cells [156]. Both tumors and stem cells are capable of selfrenewal and phenotypic plasticity[156]. The prognosis of human malignancies
often depends on the differentiation status of the tumor type with the worst
prognosis usually induced by poorly differentiated tumors. A panel of genes
identified in different histologically poorly differentiated tumors are normally
enriched in ES cells [85]. Their results indicate that genes encoding specific
transcriptional regulators in ESCs are often overexpressed in poorly
differentiated tumors. This suggests that the preventative effect of ESCs against
cancer is likely attributed to their pluripotency.
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It appears that the mechanisms involved in the prophylactic efficacy of
vaccines derived from diverse early stage embryonic cells vary to a certain
degree. When immunized with a vaccine consisting of murine ESCs along with
GM-CSF, mice display robust tumor-reactive primary and memory CD8+ T
effector responses against lung malignancy [29]. In contrast, anti-cancer
immunity of an iPSC-based vaccine is associated with reduction of a subset of
pro-inflammatory T helper cells Th17 and increased CD11b+GR1hi myeloidderived suppressor cells [30].
Immunization with antibodies specific for tumor‐associated antigens has
been reported to trigger an immunological response against tumor cells through
antibody-dependent cellular cytotoxicity (ADCC), a cell-mediated immune
defense mechanism [157-159]. In this process, membrane-surface antigens of
cancer cells are recognized by specific antibodies, leading to the interaction
between antibodies and effector immune cells as well as subsequent the lysis
of tumor cells. Since ADCC relies on a preceding antibody response to be
effective, it is part of the adaptive immune response. Although natural killer (NK)
cells are known to be the typically effector cells to eliminate neoplastic cells
during ADCC, macrophages, neutrophils and eosinophils are also capable of
mediating ADCC against cancer [160-163]. Currently, the cellular populations
responsible for ADCC in the context of ESC-derived tumor vaccines is unknown.
Therefore, further research is needed to determine the involvement of ADCC in
the prophylactic efficacy of ESC-derived anti-tumor vaccines.
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In this study, we explored the importance of pluripotency of ESCs in their
prophylactic efficacy against lung cancer. We also investigated the antigens
specific for the antibodies generated by ESC-based vaccines.
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MATERIALS AND METHODS
1. Cell lines
Murine embryonic stem cell line ES-D3 (CRL-11632) and murine Lewis lung
carcinoma (CRL-1642) were acquired from ATCC (Manassas, VA). Murine
fibroblast cell line STO (ATCC # CRL-1503) infected with a replication-defective
retrovirus expressing murine granulocyte-macrophage colony-stimulating
factor (GM-CSF) cDNA was acquired from Dr. Glenn Dranoff (Novartis Institutes
for Biomedical Research; Boston, MA). ES-D3 cells and Lewis lung carcinoma
(LLC) were cultured as described in Chapter 2. STO cells were grown and
maintained in Dulbecco's modified eagle's medium (SH30243.LS; GE Life
Sciences; Pittsburgh, PA) supplemented with 10% fetal bovine serum (900-108;
Gemini; Broderick, CA), 100 units/ml penicillin (sc45000-652; Mediatech;
Manassas, VA) and 100 µg/ml streptomycin (sc45000-652; Mediatech). GMCSF produced by STO cells was evaluated by measuring GM-CSF
concentration in the culture medium with a murine GM-CSF ELISA kit
(88733422; Thermo Fisher; Waltham, MA) following manufacturer’s protocol.
All of the cells were cultured in a 5% CO2 humidified incubator at 37oC.

2. Mice
Wild-type male and female C57BL/6 mice (8 weeks of age) were acquired from
Jackson Laboratory (Bar Harbor, ME). Mice were maintained at the University
of Louisville Research Resources Facilities (RRF). The facility is accredited by
the American Association for the Accreditation of Laboratory Animal Care
(AAALC), and adheres to the "Guide for the Care and Use of Laboratory
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Animals" (Institute of Laboratory Animal Resources, National Research Council,
National Academy Press, 1996). The Institutional Animal Care and Use
Committee (IACUC) at the University of Louisville has approved the mouse
study (protocol number: 18301).

3. Differentiation of murine ESCs
Murine ESCs were differentiated into neuronal cells following a published
protocol [164]. Briefly, ES-D3 cells were seeded onto a standard 10-cm petri
dish in standard ESC media lacking leukemia inhibitory factor (LIF) and βmercaptoethanol. Two days later, the media was replaced with fresh medium,
and the cells were cultured for 2 additional days. Next, media was replaced with
fresh media containing 0.5 M retinoic acid (R2625; Sigma-Aldrich; St. Louis,
MO) and the cells were cultured for 2 days. Finally, the cells were cultured in
fresh retinoic acid-containing media for another 2 days. The morphology of
differentiated cells was examined using an EVOS cell imaging system (Thermo
Fisher). The efficacy of differentiation was evaluated by examining the
pluripotency of differentiated cells with measurement of SSEA-1, SSEA-4 and
Oct-3/4 expression levels by flow cytometry as described in Chapter 2.

4. Anchorage-independent cell culturing
After heating in a 42°C water bath for 30 minutes, 3.5% soft agar solution was
diluted to 0.7% with fresh ES-D3 cell culture medium. To form the agar base, 3
ml of 0.7% agar solution was plated in each well of a 6-well tissue culture plate.
The agar in the plates was then solidified at 4°C for 30 minutes. Parental ESD3 cells, differentiated ES-D3 cells, and Lewis lung carcinoma (LLC) cells (3 ᵡ
103 or 7.5 ᵡ 103) were transferred on top of agar base in each well in a final
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volume of 3 ml 0.7% agar solution. Each cell line and seeding density was
plated in duplicate. The plates were placed at 4°C for 5 minutes before being
transferred to a 5% CO2 humidified incubator at 37°C for 8 day-culture. The
plates were then stained with 1 mg/ml iodonitrotetrazolium chloride (I10406;
Sigma-Aldrich) overnight. The images were acquired using an EVOS cell
imaging system and the numbers of cell colonies were determined using the
software ImageJ (National Institutes of Health; Bethesda, MD).

5. Vaccination against tumor challenge
Parental or differentiated ESCs and STO cells overexpressing GM-CSF were
disassociated from tissue culture plates with 0.05% trypsin/EDTA (25-052-CI;
Corning; Corning, NY). Collected cells were washed twice with sterile 1 x PBS
and suspended in 1 x PBS at a concentration of 10 ᵡ 106/ml. Parental or
differentiated ESCs (1 ᵡ 106) along with GM-CSF-expressing STO cells (1 ᵡ 106)
were injected subcutaneously (s.c.) in the right flank of 8-week old male or
female C57BL/6 mice. Primary vaccination was carried out on day 0, and a
boost vaccination was administered on day 7. Next, 7 days after the second
vaccination, vaccinated mice were subcutaneously administered with LLC cells
(0.15 × 106) on the left flank. Side effects of tumor development in mice were
monitored daily, and the resultant tumors were evaluated using dull-edged
Vernier calipers. Tumor growth was monitored by measuring tumor width (W)
and length (L) in mm using calipers every other day and tumor volumes (V) in
mm3 were calculated by the following formula: V = (W * W * L) / 2. Mice were
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euthanized when tumors exceeded 5% of body weight. The remaining mice
were tumor-free with no overt signs of distress. On day 72, tumor-free mice
were challenged with LLC cells (0.15 × 106) for second time by subcutaneous
injection on the left flank. Tumor growth was monitored daily.
6. Proteomics analysis of exosome samples
Exosomes isolated from ES-D3 cells were extracted with lysis buffer containing
50 mM Tris (pH7.4), 150 mM NaCl, 1% NP-40, and 0.05% SDS and stored at
4°C. Exosome lysate was analyzed at the Genome Center, University of
California at Davis. Following the standard procedure of protein digestion by
Trypsin/Lys-C (V5071; Promega; Madison, WI), exosomes were desalted by
C18 Microspin columns (SEMSS18V; Nest Group; Southborough, MA) and
lyophilized by vacuum centrifugation. Liquid chromatography (LC) separation
was carried out with an Easy-nLC 1000 LC system (Thermo Fisher Scientific).
Then

digested

peptides

were

reconstituted

in

2%

acetonitrile/0.1%

trifluoroacetic acid. The samples (3 µg) were loaded onto a 100 micron × 25
mm Magic C18 100Å 5U reverse phase trap where they were desalted online
before being separated on a 75 micron × 150 mm Magic C18 200Å 3U reverse
phase column. Peptides were eluted with a gradient of 0.1% formic acid (A) and
100% acetonitrile (B), which was run with 5% to 35% B (45 minutes), 35% to
80% B (8 minutes), 80% B (1 minute), 80% to 5% B (1 minute), and 5% B (10
minutes). The collection of mass spectra (MS) was carried out with a mass
spectrometer (Orbitrap Q Exactive Plus; Thermo Fisher Scientific) in a data117

dependent mode with MS precursor scan followed by 15 MS/MS scans. A
dynamic exclusion of 15 s was used. All MS/MS samples were analyzed using
X! Tandem (CYCLONE; 2013.02.01.1) to search the uniprot mouse proteome
plus an equal number of reverse decoy sequences (142010 entries). MS/MSbased peptide and protein identifications were validated with the software
Scaffold (Scaffold_4.8.2; Proteome Software;

Portland, OR). Peptide

identifications were accepted if they could be established at greater than 98.0%
probability by the Scaffold Local FDR algorithm. Protein identifications were
accepted if they could be established at greater than 5.0% probability to achieve
an FDR less than 5.0% and contained at least one identified peptide.
7. Antigen capture experiments for mice immunized with exosomes.
Male C57BL/6 mice (8 weeks of age, 2 mice/group) were immunized twice (day
0 and day 7) with vehicle only (1x PBS) or 225 µg of exosomes isolated from
ES-D3 cells stably-expressing GM-CSF by subcutaneous injection. Seven days
following the second vaccination, whole blood was collected by cardiac
puncture immediately after CO2 asphyxiation. Whole blood was transferred to
serum separator tubes (365967; Beckon Dickinson; Franklin Lakes, NJ) and
serum was collected. Protein A agarose beads (200 µl; 9863S; Cell Signaling;
Danvers, MA) were resuspended with 1 ml binding buffer containing 50 mM Tris
(pH7.5) and 150 mM NaCl and centrifuged at 390 x g for 30 seconds. Binding
buffer was removed and wash was repeated twice. The mouse serum collected
from 2 mice was combined (200 µl, 100 µl from each mouse) and added to the
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tubes containing the beads. The mixture was incubated on a rotator for 3 hours
at room temperature.
Exosomes isolated from ES-D3 cells expressing GM-CSF (9 mg) were
resuspended in 1.2 ml 2 X lysis buffer containing 100 mM Tris (pH7.5), 300 mM
NaCl, 2% NP-40, 0.05 % SDS, protease inhibitor (P8349; Sigma-Aldrich) and
phosphatase inhibitor (04 906 845 001; Roche Diagnostics; Indianapolis, IN).
The lysate of exosomes was first sonicated with 10% amplitude for 5 seconds
using a Sonic Dismembrator (Branson Digital Sonifier, Thermo Fisher).

The

exosomal lysate of was then passed through an insulin syringe 10 times and
centrifuged at 13,000 x g for 10 minutes at 4°C. The supernatant was taken out
as exosomal extract for the antigen binding experiment. The serum-bead
mixtures were centrifuged at 390 x g for 30 seconds at 4°C. The beads were
washed for 3 times with 500 μl of lysis buffer by rotating for 10 minutes at 4°C.
The exosomal extract (1 ml) was added to each tube containing the beads, and
the tubes were rotated at 4°C overnight. Then the extract-bead mixtures were
centrifuged at 390 x g for 30 seconds at 4°C. The beads were washed 5 times
with 1 ml of binding buffer by rotating for 10 minutes at 4°C. Abundance of
proteins bound to the beads was evaluated by proteomic analysis at the
Genome Center, University of California at Davis.
8. Antigen capture experiments for mice immunized with ESCs.
Vehicle only (1 x PBS) or ES-D3 cells (1 x 106) combined with STO-fibroblasts
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expressing GM-CSF (1 x 106) were subcutaneously injected at right flank into
eight-week old male C57BL/6 mice (2 mice/group) twice with one week apart.
One week following the second immunization, serum was collected as
described previously. Collected serum was incubated with protein A agarose
beads in the same fashion as the serum acquired from mice immunized with
exosomes as described above.
ES-D3 cells were collected (30 ᵡ 106 cells/each group) by trypsinization.
Cell pellets were resuspended in 5 ml lysis buffer and sonicated at 20%
amplitude (Branson Digital Sonifier) twice for 5 seconds each time with at least
one minute-rest on ice between each 5-second pulse. Then the cell lysate was
pushed through an insulin syringe 10 times and centrifuged in a microcentrifuge
at 13,000 x g for 10 minutes at 4°C. The supernatant was taken out as whole
cell extract for the antigen binding experiment. Whole cell extract was then
added to protein A agarose beads pre-incubated with the serum as described
above for the serum from exosome-vaccinated mice. Samples were then
examined by proteomics analysis.
9. Proteomics analysis of protein samples bound to beads
Protein samples bound to protein A agarose beads were washed four times with
200 ml of 50 mM ammonium bicarbonate (AMBIC; A6141; Sigma-Aldrich) with
a 20-minute shake at 4°C between each wash. About 2.5 µg of Trypsin/Lys-C
(V5071; Promega) was added to the beads and AMBIC mixture and the
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samples were digested overnight at 800 x rpm shake speed. Following
digestion, the supernatant was transferred to a microfuge tube and the beads
were washed once with 50 mM AMBIC. After a 20-minute gentle shake, the
wash was transferred and combined with the initial supernatant. The peptide
extracts were reduced in volume by vacuum centrifugation and a small portion
of the extract was used for fluorometric peptide quantification (23290; Thermo
Fisher Scientific). One microgram of sample based on the fluorometric peptide
assay was loaded for each LC-MS analysis.
Digested peptides were analyzed by LC-MS/MS on a Thermo Scientific Q
Exactive Orbitrap Mass spectrometer in conjunction Proxeon Easy-nLC II
HPLC (Thermo Fisher Scientific) and Proxeon nanospray source. The digested
peptides were loaded a 100 micron x 25 mm Magic C18 100Å 5U reverse phase
trap where they were desalted online before being separated using a 75 micron
x 150 mm Magic C18 200Å 3U reverse phase column. Peptides were eluted
using a 60-minute gradient with a flow rate of 300 nl/min. An MS survey scan
was obtained for the m/z range 300-1600, MS/MS spectra were acquired using
a top 15 method, where the top 15 ions in the MS spectra were subjected to
HCD (High Energy Collisional Dissociation). An isolation mass window of 2.0
m/z was for the precursor ion selection, and normalized collision energy of 27%
was used for fragmentation. A 15-second duration was used for the dynamic
exclusion.
Tandem mass spectra were extracted and charge state was deconvoluted
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by Proteome Discoverer (Thermo Fisher Scientific). MS/MS samples were
analyzed using X! Tandem (The GPM, thegpm.org; version TORNADO
(2013.02.01.1)). X! Tandem was set up to search (20180405 Uniprot Mouse)
database (108924 entries), the cRAP database of common laboratory
contaminants (www.thegpm.org/crap; 114 entries) plus an equal number of
reverse protein sequences assuming the digestion enzyme trypsin. X! Tandem
was searched with a fragment ion mass tolerance of 20 PPM and a parent ion
tolerance of 20 PPM. Deamidation of asparagine and glutamine, oxidation of
methionine and tryptophan, sulphone of methionine, tryptophan oxidation to
formylkynurenin of tryptophan and acetylation of the n-terminus were specified
in X! Tandem as variable modifications.
Scaffold (version 4.4.1, Proteome Software) was used to validate MS/MSbased peptide and protein identifications. Peptide identifications were accepted
if they could be established at greater than 85.0% probability by the Scaffold
Local FDR algorithm. Protein identifications were accepted if they could be
established at greater than 80.0% probability to achieve an FDR less than 5.0%
and contained at least 1 identified peptide. Protein probabilities were assigned
by the Protein Prophet algorithm (reference). Proteins that contained similar
peptides and could not be differentiated based on MS/MS analysis alone were
grouped to satisfy the principles of parsimony. Proteins sharing significant
peptide evidence were grouped into clusters.
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10. Statistical analysis
All of the experiments were performed in replicates. The statistical analysis was
carried out by the student t-test and the analysis of variance (ANOVA). A P value
< 0.05 was considered significant.
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RESULTS
1. The pluripotency of murine embryonic stem cells (ESCs) is reduced
during differentiation
ESCs and lung cancer cells express common protein markers and share
several genotypic and phenotypic traits [11, 18, 165]. Among them, pluripotency
is one of the most specialized properties shared between ESCs and a subset
of lung tumor cells, cancer stem cells (CSCs). We reasoned that the anti-lung
tumor immunity generated by ESC-based vaccine, either as intact cells or as
secreted exosomes, is likely attributed to shared carcinoembryonic antigens
whose expression is reduced or eliminated during differentiation. A published
approach was employed to differentiate murine ESC line ES-D3, in which
deprivation of extrinsic self-renewal signals from leukemia inhibitory factor (LIF)
coupled with the addition of retinoic acid drove undifferentiated cells to become
neuronal cells [164, 166]. Morphological characterization of parental and
differentiated ES-D3 cells was carried out using microscopy (Figure 4.1A).
Undifferentiated parental ES-D3 cells had morphology of typical ESCs with
rounded cell shape and smooth cytoplasmic membrane, and they generated
close cytoplasmic membrane contact with each other to form colonies [167]. In
contrast, differentiated ES-D3 cells displayed different morphology with
dendrite-like protrusions, which is consistent with the morphological
characteristics of neuronal cells [168].
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A number of molecular markers have been reported to be indicative of the
pluripotency of murine ESCs, among which SSEA-1, SSEA-4, and Oct-3/4
expression are commonly studied to examine the pluripotency status [169].
Generally, pluripotent murine ESCs exhibit elevated SSEA-1 and Oct-3/4
reactivity, but low expression of SSEA-4 [170]. Therefore, the pluripotency of
differentiated ES-D3 cells was evaluated by measuring SSEA-1, SSEA-4 and
Oct-3/4 expression levels via flow cytometry as described earlier (Figure 2.3).
Loss of pluripotency of differentiated ES-D3 cells was indicated by decreased
SSEA-1 and Oct-3/4 expression and increased SSEA-4 expression compared
with parental ES-D3 cells (Figure 4.1B). Overall, differentiated ES-D3 cells are
distinct from their undifferentiated counterparts at both morphological and
molecular levels.
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Figure 4.1. Differentiated ES-D3 cells are characterized.
Murine embryonic stem cell line ES-D3 cells were cultured in the absence of
LIF and β-mercaptoethanol for 4 days. Then ES-D3 cells were cultured in
the presence of 0.5 mM retinoic acid for 4 days. (A) Representative images
of parental and differentiated ES-D3 cells. Scale bar, 10 µM. (B) Flow
cytometry analysis of the expression of pluripotency and differentiation
markers (SSEA-1, Oct3/4 and SSEA-4) in parental and differentiated ES-D3
cells.
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2. The pluripotency of ESCs is important for their anchorage-independent
growth potential
A hallmark of tumorigenesis is the proliferation of neoplastic cells without a solid
surface, aka anchorage-independent growth, which correlates with tumorigenic
and metastatic potential in vivo [171]. The soft agar colony formation assay is
a well-accepted method to evaluate anchorage-independent growth [172]. Due
to anoikis, a particular type of apoptosis, no colonies are formed when normal
cells are plated in an anchorage-independent culture model [173]. Although
ESCs and malignant cells share some genotypic and phenotypic traits, it was
unclear whether ESCs possess anchorage-independent growth potential, as
tumor cells do. Equal numbers of parental ES-D3 cells and Lewis lung
carcinoma (LLC), an aggressive non-small cell lung cancer cell line, were
seeded in soft agar. As shown in Figure 4.2, LLC cells and parental ES-D3 cells
showed similar anchorage-independent growth capacity. To our knowledge, this
is the first study demonstrating that the anchorage-independent growth
potential of undifferentiated ESCs is the same as that of lung tumor cells. To
further explore the involvement of pluripotency of ESCs in anchorageindependent cell growth, we examined the ability to form colonies in soft agar
of differentiated ES-D3 cells, which was reduced to extremely low levels
compared with those of undifferentiated ES-D3 and LLC cells. These results
indicate that pluripotency of ESCs is critical for their ability to evade anoikis and
grow independent of a solid surface.
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Figure 4.2. Differentiation inhibits anchorage-independent proliferation
of ES-D3 cells.
The anchorage-independent growth capability of differentiated ES-D3 cells
and their parental counterparts was examined by a soft agar colony
formation assay. (A) The indicated number of LLC, parental ES-D3 cells and
differentiated ESD3 cells were cultured in soft agar for 8 days.
Representative images of the plates are shown. (B) The colonies of LLC,
parental ES-D3 and differentiated ES-D3 on the soft agar plates shown in
(A) were counted. The data are presented as means ± standard deviations
of three independent experiments. Student's unpaired t test. Asterisks (**),
indicate p < 0.001. “ns”, no significance.
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3. Differentiation decreases the efficacy of ESC vaccine on lung tumor
development
Once the reduction in pluripotency of ES-D3 cells by differentiation was
confirmed, the role of pluripotency in anti-tumor efficacy of ES-D3 cells was
evaluated. To ensure rigor and reproducibility, animal studies were designed to
include appropriate control and treatment groups with both sexes. To achieve
power and statistical significance, there were 8 animals in each experimental
group. Subcutaneous (s.c) injection of vaccines was carried out to induce
immunization as described earlier [29]. Three groups of C57BL/6 mice were
immunized (aged 8 weeks, 8 per sex per group): vehicle control (1 x PBS),
undifferentiated ES-D3 and STO fibroblasts expressing GM-CSF (UNDIFF +
STO ) or their differentiated counterparts along with GM-CSF-expressing STO
cells (DIFF + STO ). Mice were immunized twice (day 0 and day 7) followed by
a challenge with subcutaneous injection of highly aggressive LLC cells (0.15 ×
106) at day 14. The kinetics of tumor growth were closely monitored by
measuring both the longitudinal and transverse diameters of tumors using
digital calipers every 2 days as described above. As depicted by Kaplan-Meier
survival curves shown in Figure 4.3, all non-vaccinated control animals died
within 28 days of tumor cell challenge, whereas 56% of mice vaccinated with
undifferentiated ES-D3 cells survived beyond 38 days. Importantly, only 31% of
animals immunized with differentiated ES-D3 survived for the 28-day period,
indicating that differentiation decreases the cancer prevention efficacy of ESCs.
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Furthermore, the results obtained from male mice are very comparable with
those from female mice. In the case of tumor development, all control mice
developed tumors 14 days after LLC cell administration (Figure 4.4). In contrast,
56% (n=16) of mice vaccinated with undifferentiated ES-D3 cells were
protected from tumor outgrowth by day 32 post-challenge. Moreover,
differentiated ES-D3 cells vaccination decreased the efficacy of the
immunization against lung cancer by 31% compared to undifferentiated ES-D3
cells. Tumor growth patterns were similar between both sexes.
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Figure 4.3. Differentiation decreases the efficacy of ES-D3 cells against
lung cancer.
(A) The scheme of immunization is shown. Male and female C57BL/6 mice
were immunized twice with 1 x PBS (vehicle control), parental ES-D3/STO
expressing GM-CSF (UNDIFF + STO) or differentiated ES-D3/STOexpressing GM-CSF (DIFF + STO) prior to s.c. challenge with LLC cells (0.15
× 106). Tumor growth was monitored daily in all mice until they were
euthanized due to tumors exceeding 5% of body weight. (B) Kaplan-Meier
survival curve demonstrates the probability of tumor-free survival in male
mice (n=8). (C) Kaplan-Meier survival curve compares the survival of female
mice in different vaccination groups (n=8). (D) The data shown in (B) and (C)
are combined (16 mice/group).
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Figure 4.4. Differentiation of ES-D3 cells inhibits their ability to prevent
lung cancer.
C57BL/6 mice were vaccinated twice (days 0 and 7) with 1 x PBS (vehicle
control), parental ES-D3/STO expressing GM-CSF (UNDIFF + STO) or
differentiated ES-D3/STO expressing GM-CSF (DIFF + STO) followed by
s.c. injection of 0.15 × 106 LLC cells on day 14. Tumor growth was examined
daily. (A) The percentage of tumor-free male mice (8 mice/group) are shown.
(B) The data of tumor occurrence in female mice (8 mice /group) are
presented (C) Tumor development in both male and female mice is
evaluated (16 mice/group, 8 mice/gender).
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More importantly, the growth of LLC tumors that developed in mice
vaccinated with undifferentiated ES-D3 cells was slower compared with those
of non-vaccinated control mice and mice immunized by differentiated ES-D3
cells (Figure 4.5). These results lend more credence to the notion that the
differentiation of ESCs decreases their anti-tumor efficacy in mice.
A

B

C

Figure 4.5. Differentiation reduces anti-cancer activities of ES-D3 cells.
C57BL/6 mice were injected twice (days 0 and 7) with 1 x PBS (vehicle
control), parental ES-D3/STO expressing GM-CSF (UNDIFF + STO) or
differentiated ES-D3/STO expressing GM-CSF (DIFF + STO). On day 14,
LLC cells (0.15 × 106) was inoculated into mice by s.c. injection. Tumor
growth was determined by dull-edged Vernier calipers every two days.
Tumor volumes are presented as means ± standard deviations. The data
represent male mice (A), female mice (B) and both genders (C).
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To evaluate the involvement of ESC pluripotency in the generation of longterm immunity against lung cancer, we tested the anti-tumor responses using
mice that had been vaccinated and protected successfully for 58 days. The
previously LLC-challenged tumor-free mice were injected with LLC cells for a
second time (Figure 4.6A). Notably, 2 tumor-free mice vaccinated with
differentiated ES-D3 cells developed tumors 8 days after the second LLC
challenge, whereas only 20% of mice (n=8) in the UNDIFF+STO vaccination
group developed tumors following LLC cell re-inoculation (Figure 4.6B). This
provides evidence that the pluripotency of ESCs is essential for their long-term
anti-tumor activities.
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Figure 4.6. Differentiation decreases long-term cancer prevention
potential of ES-D3 cells
(A) The scheme of vaccination is shown. tumor-free C57BL/6 mice were
immunized with parental ES-D3/STO expressing GM-CSF (UNDIFF + STO)
or differentiated ES-D3/STO expressing GM-CSF (DIFF + STO) twice (days
0 and 7), followed by injection inoculation of 0.15 × 106 LLC cells on day 14.
Tumor-free mice were challenged again with LLC cells (0.15 × 10 6) again at
day 72. Tumor development was monitored daily until sacrifice due to tumor
sizes reaching the limit (5% of body weight). (B) 28 days after second LLC
challenge, the percentages of tumor-free mice in each group were
determined.
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4. ES-D3 cells and lung tumor cells exhibit antigenic similarity as revealed
by antigen capture experiments
There is abundant evidence that malignant cells and ESCs share
carcinoembryonic antigens, which are not expressed in normal adult tissues
[18]. Those antigens play an important role in cancer vaccination, as they
enable the immune system to distinguish tumor cells from nontumor cells,
resulting in potential cancer rejection. Since exosomes derived from murine
ESCs engineered to produce GM-CSF significantly slowed or blocked the
outgrowth of implanted LLC (Figure 2.6), we first examined the presence of
proteins in exosomes derived from ES-D3. As shown in Table 4.1, tumor
antigens identified in a variety of tumor types, such as alpha fetoprotein (AFP),
lactate dehydrogenase (LDH) and fibrinogen, were also present in exosomes
derived from ES-D3 cells [174-180], which is in agreement with the notion that
embryos and tumors share a group of similar antigens [19, 97, 98].
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Table 4.1 Exosomes derived from ES-D3 cells contains various tumor
antigens.
Tumor antigens presented in exosomes isolated from ES-D3 cells were
identified by a proteomics approach.
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Since the antigens responsible for prophylactic efficacy of intact ES-D3
cells or exosomes isolated from ES-D3 cells have not been identified yet, we
carried out a series of experiments to thoroughly explore this issue. It is possible
that the antibodies generated by ESC-based vaccine directly recognize
neoplastic cells and initiate antibody-dependent cellular cytotoxicity (ADCC). To
gain a comprehensive understanding of the antigenicity of ESC vaccine, a novel
immunoproteomic strategy was employed (Figure 4.7). This approach has the
potential to reveal the complete repertoire of potentially immunogenic antigens
in the serum of immunized mice. This combined affinity chromatography
shotgun immunoproteomic approach starts with capture of antibodies in the
serum by an IgG affinity column [181]. Specifically, mice (C57BL/6) were
immunized with either a cell-based vaccine (ES-D3 cells + STO expressing GMCSF) or an exosome-based vaccine (exosome from GM-CSF-expressing ESD3) as described in “Materials and Methods”. After the binding of antibodies to
protein A beads, antigen-containing ESC lysates or exosomal lysates were
loaded to the respective mixture of protein A beads and antibodies from serum.
Bound antigens were identified by liquid chromatography tandem mass
spectrometry (LC-MS/MS) analysis.
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Figure 4.7. An immunoproteomics strategy to identify the antigens
specific for the antibodies generated by vaccines derived from ESCs.
The schematic description of a combined affinity chromatography shotgun
immunoproteomics approach. C57BL/6 mice were immunized with a vaccine
composed of ES-D3 cells and STO fibroblasts expressing GM-CSF) or a
vaccine composed of exosomes from GM-CSF expressing ES-D3 cells.
Lysates containing antigens of cell- or exosomes-based vaccine were loaded
to Protein A agarose beads bound with serum antibodies. LC-MS/MS studies
were conducted to identify the antigens bound to the beads
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For the serum acquired from the mice vaccinated with the cell-based
vaccine, the presence of 136 immunoglobin-unrelated proteins in the serum of
immunized mice is higher than their control counterparts (Figure 4.8A). Among
them, 16 identified proteins are members of keratin family and 11 keratin types
are cancer related (Table 4.2). Although keratin members are fibrous proteins
that form the structural framework of epithelial cells, some of them are
commonly used as diagnostic markers for cancers with various epithelial origins,
due to their distinctive expression patterns [182]. Importantly, several keratin
proteins associated with lung malignancy, keratin 7, 8, 16, 17, and 19, were
identified in the serum of mice vaccinated with intact ES-D3 cells (Table 4.3).
Similarly, the exosome-based vaccine generated antibodies recognizing
132 non-immunoglobin proteins compared with the vehicle control (Figure
4.8B). Consistent with the results acquired from the cell-based vaccine, a large
portion of identified antigens (25 out 132) are keratin members. 10 of which are
cancer related (Table 4.2). Furthermore, lung tumor-associated keratin
members 8, 14, 16, and 17 were also enriched in the serum of exosomeimmunized mice (Table 4.3).
To further evaluate the potential involvement of lung cancer-associated
keratin proteins in anti-lung tumor immunity evoked by ESC vaccines, the
protein expression profile of LLC cells was examined by a proteomics approach.
As expected, several keratins linked to lung tumorigenesis (keratin 7, 8, 16, 17
and 18) were found to express in LLC cells (Table 4.3). These data suggest that
142

keratin members (8, 16, and 17) are candidate antigens responsible for
initiating anti-lung tumor immunity through ADCC.

A

B

Figure 4.8. Summary of identified antigens specific for vaccinegenerated antibodies.
Antigens

were

identified

by

an

affinity

chromatography

shotgun

immunoproteomics strategy. (A) Numbers of antigens presented in the
serum of mice immunized with cell-based vaccine. (B) Numbers of antigens
presented in the serum of mice immunized with exosome-based vaccine.
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Table 4.2. Keratin members recognized by antibodies in the serum of
immunized mice.
Keratin members recognized by antibodies in the serum of mice immunized
with cell-based vaccine or exosome-based vaccine are listed.
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Table 4.3. Keratin members as candidate antigens responsible for the
vaccination efficacy of ES-D3- derived vaccines.
The list includes lung cancer-associated keratin members identified in the
serum of immunized mice or lung cancer cells (LLC). Those present in both
the serum and LLC are marked in red.
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DISSCUSION
The generation of different types of tumors is a complex processes in which
tumors acquire the ability of dynamic regulation and constituent cellular
populations, recapitulating the complexity of organs or tissues [183]. For a long
time, embryonic materials have been considered as a vaccine against cancers
based on the similarities between embryos and tumors [18]. It has been found
that some genes expressed in histologically poorly differentiated tumors cells
are overexpressed in ESCs, and vice versa [85]. The identification of CSCs
indicates that some tumor cells have the properties of stem cells to generate
tumors [156]. In our study, parental ES-D3 cells display robust anchorageindependent growth capability (Figure 4.2), a key signature of tumorigenesis
that correlates with tumorigenic and metastatic potential in animals [171]. This
suggests that the signaling transduction pathway(s) governing cell proliferation
in ESCs is similar to that in neoplastic cells. Importantly, a decrease in the
pluripotency of ESCs completely abolished their anchorage-independent
growth potential, lending more support for the importance of ESC pluripotency
in regulating the cellular phenotypes shared with tumor cells.
Anti-tumor immunity is the most crucial factor in the prevention of
tumorigenesis by the vaccination of ESCs. Furthermore, the similarity between
ESC antigens and tumor antigens is considered to be responsible for inducing
the immune responses against malignancy. In our study, vaccination with
parental ESCs inhibited lung tumor development, whereas the differentiation of
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ESCs suppressed the efficacy of the vaccine (Figure 4.3). As the protection
against lung cancer conferred by ESC vaccination likely involves a number of
shared antigens, it is conceivable that differentiation could decrease expression
of tumor antigens on ESCs, leading to a reduction in cross-immunity against
tumors. This is in agreement with the differentiation-evoked loss of tumor cell
signatures in ESCs, such as anchorage-independent growth. However, the
identities of specific cross-reactive antigens and their gene expression
modulation need to be investigated in future studies.
To explore the tumor-associated antigens shared between ES-D3 cells and
malignant cells, we examined the comprehensive profiles of antigens specific
for the antibodies induced by vaccines based on intact ES-D3 cells or
exosomes of ES-D3 cells by an immunoproteomic approach (Table 4.2). This
analysis reveals that ES-D3 cells and lung cancer cells share expression of a
number of proteins implicated in tumorigenesis, which are candidate crossreactive antigens evoking anti-tumor immunity. Interestingly, none of the
antibodies against tumor-antigens present in exosomes of ES-D3 cells (Table
4.1) are enriched in the serum from immunized mice, suggesting that those
antigens are likely involved in generating anti-lung cancer immunity through
other mechanisms, such as promoting cytotoxic T cell responses against
pulmonary malignancy.
Our studies indicate the anti-tumor efficacies of both ESC cell-based or
exosome-based vaccines were correlated with significantly enhanced T cell147

mediated immune responses, including stronger Th1-mediated cytokine
responses in splenic CD8+ T cells and higher CD8+ T/Tregs cell ratio in tumors
[29], (Figures 2.10, 2.12). However, whether the humoral immune response
mediated by antibodies also contributes to anti-cancer efficacy of ESC
vaccination strategy remains unknown. Interestingly, a similar iPSC vaccine
indeed produced antibodies specifically reactive to tumors cells [30]. Thus, it is
possible that antibodies generated by ESC-based vaccine recognize the
antigens on lung tumor cells to evoke ADCC-mediated anti-tumor immunity.
A large portion of antigens identified by immunoproteomic analysis are
keratin family members, which are proteins forming intermediate filaments in
epithelial cells [182]. Notably, the expression of keratin proteins is crucial for
uncontrolled proliferation of malignant cells of epithelial origin within anaplastic
cancers. Keratins have been extensively used in clinical tumor diagnosis as
immunohistochemical markers since 1980 [184]. Importantly, in the assessment
of different types of cancer metastases, the expression patterns of keratin
subtypes could be utilized to predict the origin of primary tumors [182]. Since it
was discovered that keratins are expressed in all epithelial cells [185], several
members of keratins, including keratin 7, 8, 16, 17, 18 and 19, have
subsequently been identified as markers of lung cancer [186-188].
Notably, keratin 8, 16, and 17 are among the lung cancer-associated keratin
family members whose levels in serum are enhanced by both the cells-based
vaccine as well as the exosome-based vaccine (Table 4.3). Since these keratin
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proteins are also present in LLC cell lysate, they are likely to be the candidate
antigens evoking immunity against LLC. Based on clinical research, the
expression of keratin 8 is significantly higher in patients with non-small cell lung
cancer (NSCLC) compared with small cell lung cancer (SCLC) patients [189].
It has been concluded that high expression of keratin 8 enhances tumor
progression and indicates poor prognosis [189].
Although keratin proteins form intermediate filaments are inside cells,
emerging evidence indicate that some keratin family members are localized on
cell surface. For instance, the presence of keratins 8, 18 and 19 were detected
on the outer surface of human mammary carcinoma cells as well as in culture
medium [190]. Similarly, keratin 8 is expressed at the surface of lung carcinoma
cells, but not in normal epithelial cells [191]. Furthermore, fragments of keratin
8 released by lung cancer cells were utilized as an indicator of tumor
progression in clinical studies [192, 193]. Importantly, the interaction between
keratin 8 and MHC class I was involved in CD8+ T cell activation in a lymph
node metastatic carcinoma cell line [194]. It is conceivable that keratin 8
molecules on lung tumor cell surface are recognized by specific antibodies
generated by ESC-based vaccine, resulting in recruitment of effector immune
cells and subsequent tumor cell apoptosis.
As a member of the type I cytokeratins, keratin 16 has been found to
associate with squamous differentiation [195]. A recent study demonstrates that
keratin 16 possesses oncogenic activity to promote the tumorigenesis of lung
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adenocarcinoma and is considered to be a predictive factor of poor patients
prognosis

[196,

197]. Accumulating

studies

indicate

keratin

17

is

overexpressed in a number of malignancies and plays an important role in the
progression of tumors [197-200]. For example, it has been found that the mRNA
level of keratin 17 is significantly elevated in lung carcinoma tissues compared
with normal lung tissues. Markedly, metastasis and poor survival of lung cancer
patients is correlated with high expression of keratin 17 [200]. Unlike keratin 8,
the presence of keratins 16 and 17 on the surface of lung tumor cells remains
unknown. More studies are needed to address how keratins 16 and 17 are
involved in ESC vaccine-evoked ADCC.
Overall, our studies reveal an important role of pluripotency of ESCs in antilung cancer efficacy afforded by ESC-based vaccines. Furthermore, several
keratin family members were identified as candidate cross-reactive antigens to
confer immunity against lung cancer. Future research is warranted to elucidate
the mechanisms of immunity against lung neoplastic diseases evoked by ESCbased vaccination.
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LIST OF ABBREVIATIONS

ADCC

antibody-dependent cellular cytotoxicity

AFP

alpha fetoprotein

ALP

alkaline phosphatase

ALT

alanine transaminase

APCs

antigen-presenting cells

BUN

blood urea nitrogen

CAR

chimeric antigen receptor

CBC

complete blood count

CEA

carcinoembryonic antigen

CICs

cancer-initiating cells

CISH

cytokine inducible SH2domain

CRC

colorectal carcinoma

CSCs

cancer stem cells

CSF

colony-stimulating factors

CTA

cancer/testis antigen

CTL

cytotoxic T lymphocyte

CTLA

cytotoxic T lymphocyte antigen
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DCs

dendritic cells

Dexosomes

dendritic cell-derived exosomes

EF1a

elongation factor-1a

EGFR

epidermal growth factor receptor

ESCs

embryonic stem cells

ES-exo/GM-CSF

ESC-derived exosomes bearing GM-CSF

EVs

extracellular vesicles

FDA

Food and Drug Administration

GM-CSF

granulocyte macrophage-colony stimulating factor

G-MDSCs

granulocytic myeloid derived suppressor cells

HBV

human hepatitis B virus

HPV

human papilloma virus

HSPs

heat shock proteins

IACUC

institutional animal care and use committee

ICAM-1

intercellular cell-adhesion molecule-1

IL

interleukin

INF

interferon

iPSCs

induced pluripotent stem cells

LDH

lactate dehydrogenase

LIF

leukemia inhibitory factor

LLC

Lewis lung carcinoma

MAGE

melanoma-associated antigen
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MDSCs

myeloid derived suppressor cells

MHC

major histocompatibility complex

M-MDSCs

monocytic myeloid derived suppressor cells

MVBs

multivesicular bodies

NK

natural killer

NOD-SCID

non-obese

diabetic

severe

combined

immunodeficiency
NSAID

non-steroidal anti-inflammatory drug

NSCLC

non-small cell lung carcinoma

PD-1

programmed cell death protein 1

PDI

protein disulfide isomerase

PD-L1

programmed cell death protein ligand 1

PSA

prostate-specific antigen

s.c.

subcutaneous

STAT5

signal transducer and activator of transcription 5

STR

short tandem repeat

TAAs

tumor-associated antigens

Tc

cytotoxic T cells

TEM

transmission electron microscopy

Texosomes

tumor-derived exosomes

TGF

transforming growth factor

Th

T helper cell
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TIL

tumor-infiltrating lymphocytes

TLR2

toll like receptor 2

TLR4

toll like receptor 4

TNF-α

tumor necrosis factor alpha

TRAIL

TNF-related apoptosis-inducing ligand

Tregs

T regulatory cells
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